MULTIFUNCTIONAL AND BIOLOGICALLY ACTIVE MATRICES FROM MULTICOMPONENT POLYMERIC SOLUTIONS

Inventors: Kristi L. Kiick, Rising Sun, MD (US); Nori Yamaguchi, Newburgh, IN (US); John Rabolt, Wilmington, DE (US); Cheryl Casper, Blackwood, NJ (US)

Assignee: University of Delaware, Newark, DE (US)

Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 213 days.
This patent is subject to a terminal disclaimer.

Prior Publication Data
US 2010/0297238 A1 Nov. 25, 2010

Related U.S. Application Data
Provisional application No. 60/666,787, filed on Mar. 31, 2005.

Int. Cl.
A61K 31/727 (2006.01)
A61K 31/715 (2006.01)
A61K 38/00 (2006.01)
C08B 37/10 (2006.01)

U.S. Cl. ............... 514/56; 514/54; 514/23; 536/21; 424/488; 424/486

Field of Classification Search: 514/56, 514/54, 23, 2; 536/21; 424/488, 486
See application file for complete search history.

References Cited

U.S. PATENT DOCUMENTS
6,541,033 B1 * 4/2003 Shah ......................... 424/486

OTHER PUBLICATIONS
Hedberg et al. (Journal of Controlled Release (2002), 84(3), 137-150).*
Arakawa et al. (Archives of biochemistry and biophysics, (Jan. 1994) vol. 308, No. 1, pp. 267-273) (Abstract sent).*

* cited by examiner

Primary Examiner — Shaojia Anna Jiang
Assistant Examiner — Michael C Henry
Attorney, Agent, or Firm — McCarter & English

ABSTRACT
A functionalized electrospun matrix for the controlled-release of biologically active agents, such as growth factors, is presented. The functionalized matrix comprises a matrix polymer, a compatibilizing polymer and a biomolecule or other small functioning molecule. In certain aspects the electrospun polymer fibers comprise at least one biologically active molecule functionalized with low molecular weight heparin.

12 Claims, 18 Drawing Sheets
Figure 1

Figure 2

A

B
Figure 3

Figure 4
FIGURE 9

Bar chart showing optical density (OD) for different types of fibers:
- PLGA Fibers
- LMWH/PLGA Fibers
- PEG-LMWH/PLGA Fibers
After 6 h incubation in PBS

After 1 day incubation in PBS

After 3 days incubation in PBS

After 14 days incubation in PBS

**FIGURE 10**
After 6 h incubation in PBS

After 1 day incubation in PBS

FIGURE 11 (a-d)
PEG-LMW-Dye/PLGA

LMWH-Dye/PLGA

After 3 days incubation in PBS

PEG-LMW-Dye/PLGA

LMWH-Dye/PLGA

After 14 days incubation in PBS

FIGURE 11 (e-h)
FIGURE 12
FIGURE 14
FIGURE 15

Graph showing OD (450nm) against culture times (days) for PLGA, LMWH/PLGA, and PEG-LMWH/PLGA.
FIGURE 17
FIGURE 20

FIGURE 21
FIGURE 22

FIGURE 23
FIGURE 24

A. PDGF

B. VEGF

C. bFGF

- Polymer Alone
- Polymer-HMWH
- Polymer-LMWH
- Polymer-PEGLMWH

Days

Percent Release
MULTIFUNCTIONAL AND BIOLOGICALLY ACTIVE MATRICES FROM MULTICOMPONENT POLYMERIC SOLUTIONS

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/666,787, filed Mar. 31, 2005, and U.S. patent application Ser. No. 11/385,699, filed Mar. 31, 2006 now U.S. Pat. No. 7,732,427, of which it is a continuation-in-part. The contents of each of these priority applications are incorporated herein by reference.

RELATED FEDERALLY SPONSORED RESEARCH

The work described in this application was sponsored by the following Federal Agencies: NSF NIRT under Contract Number DMR-0210223, NASA under Contract Number NAGS-01923, NIH, Nanoscale Engineering, under Contract Number RO1 EB003172, and NIH under Contract Number RO1-EB006006.

FIELD OF THE INVENTION

The present invention relates generally to a composition and method for the formation of functionalized polymer matrices comprising a matrix polymer, a compatibilizing polymer and a biomolecule or other small functioning molecule. In a more specific embodiment, the invention includes heparin-containing electrospun polymeric fibers useful in biological applications, for example, implantable systems for drug delivery, tissue engineering or wound repair. In other aspects the present invention relates to multicomponent polymer matrices that display biologically beneficial properties, for example, by also comprising therapeutic molecules therein. In another important aspect the invention relates to a polymer matrix, useful for the controlled release of a biologically active agent, such as for example, a drug, a biopolymer, a biological macromolecule, and the like. The invention is further directed to the formation of functionalized cross-linked matrices, such as hydrogels, that include at least one functionalized compatibilizing polymer capable of assembly.

BACKGROUND OF THE INVENTION

Over the past two decades the development of novel drug delivery systems has had a tremendous impact on medicine, allowing for the improvement of many existing therapeutics as well as enabling the use of entirely new therapies. Along with these improvements there has been a move to miniaturize drug delivery devices from the macroscale (>1 mm) to the microscale (100-0.01 µm) or nanoscale (100-1 nm). One goal of developing these devices is to provide for the in situ delivery of therapeutic compounds. Therefore, a main area of investigation concerns the development of integrated systems that combine the nanotechnology with therapeutic molecules, for example, drugs, or biopolymers.

However, these new technologies must overcome several crucial and significant obstacles. For example, new approaches are required that allow for the delivery of insoluble, or unstable compounds. In addition, these approaches must address situations in which the therapeutic molecule is rare, or difficult to purify. Furthermore, these approaches must allow for localized delivery of potent compounds, and provide for improved compliance by reducing the chances of missing or erring in a dose. Lastly, these devices cannot be so small that they are unable to deliver an adequate dose.

In addition, to date a number of peptides and proteins have been explored for pharmaceutical applications by virtue of their high biological activity and specificity. Despite potential advantages offered by these drugs, their application may suffer because of the high molecular weight, hydrophilicity and low stability, which are reflected in poor biopharmaceutical properties. In particular, peptides and proteins undergo rapid clearance from the body, which takes place by a combination of events including proteolysis, renal ultrafiltration, and liver clearance.

The development of functionalized polymers that can elicit specific biological responses, as well as the development of methods to fabricate these biologically functionalized polymers, is a viable approach for such therapeutic applications, in which delivery of molecules such as those above is desirable. For example, the generation of fibrous matrices with biological properties and fiber diameters commensurate with those of the natural extracellular matrix (ECM) may permit the development of novel materials for use not only in drug delivery, but also in wound healing or tissue engineering.

Synthetic polymers, which can be designed to mimic some functions of biopolymers, have been actively developed as drug delivery matrices due to their industrial and scientific value. They represent a primary polymeric vehicle for the delivery of drugs and biomolecules, owing to their simple synthesis, ease of processing, and range of physical properties. Polymers such as proteins, polysaccharides, and nucleic acids, which are present as basic components in living organic systems, have also found some use in drug delivery and biomaterials applications, particularly for biopolymers such as collagen and alginate, which have desired mechanical and biological properties. There remains a significant need, however, for the facile production of polymeric materials in which mechanical and biological properties can be easily modified in a modular fashion, without relying solely on the naturally occurring mechanical properties of the biological polymers or the lack of biological activity of synthetic polymers.

One approach to the use of polymers in drug delivery applications involves the response of a polymer system to certain stimuli, which is a common process for biopolymers in living organisms. Stimuli responsive polymers can provide a variety of applications for the biomedical fields. The interest in these polymers has increased dramatically due to their promising potential. Among others, temperature and pH responsive mechanisms have been investigated as they are relatively convenient and effective stimuli in a variety of applications. Such stimuli-responsive polymers have been utilized in various forms, including cross-linked (permanently) hydrogels, reversible hydrogels, micelles, modified interfaces, and conjugated solutions, among others.

There has also been developing interest by the scientific community in applying methods from engineering and the life sciences to create artificial constructs directed to tissue regeneration, and thus, providing a minimally invasive and less painful way to treat patients. The basic protocol for the tissue engineering approach includes isolating specific cells by obtaining them through a biopsy from a patient, growing them on a three-dimensional scaffold under controlled culture conditions, delivering the construct to the desired location in the patient’s body and directing new tissue formation into the scaffold that will be degraded over time. Successful regeneration of damaged organs or tissues based on tissue
engineering requires several critical elements, not the least of which includes biomaterial scaffolds that serve as a mechanical support for cell growth.

Materials are important in most tissue engineering strategies as they can serve as a substrate on which cell populations can attach and migrate, be implanted with a combination of specific cell types as a cell delivery vehicle, and be utilized as a drug carrier to activate specific cellular function in the localized region.

The modification of biomaterials with bioactive molecules has been found useful in designing biomimetic scaffolds that can provide biological cues to elicit specific cellular responses and direct new tissue formation. The surface and bulk modification of materials with peptide sequences or with bioactive proteins or other biomolecules, for example, can allow for the modulation of cellular functions such as adhesion, proliferation and migration through alterations of peptide concentration or its spatial distribution. A variety of cell binding peptides have been introduced into three-dimensional networks through physical, chemical, photochemical, and ionic cross-linking. The molecules have been attached to a variety of polymeric substrates for varying applications, but a need still remains for methods for simple modification of materials with multiple bioactive molecules in a manner that can control their release.

Electrospinning is an attractive approach to polymer processing. The control of fiber diameter, porosity, and fiber surface morphology makes electrospun fibers useful in a range of applications including filtration, electrospinning, and biomedical applications. Electrospun fibers are ideal for use in biomedical applications such as tissue engineering and drug delivery due to the three-dimensional nanometer scale matrix that can be quickly produced using small quantities of starting material (<50 mg) on the laboratory scale. Larger matrices can also easily be made via the scaling up of materials that prove to have useful materials and biological properties on the laboratory scale. Collagen, fibrinogen, chitosan, poly(lactic acid), poly(1-lactide-co-β-caprolactone), and poly(DL-lactide-co-glycolide) are just a few of the polymers being investigated for use in electrospun drug delivery and tissue engineering constructs due to their biocompatibility. Electrospun fibers mimic the size scale of fibrous proteins found in the extracellular matrix (50-150 nm) and the three-dimensional nature of the matrix allows for cells to infiltrate the matrix and proliferate. A variety of additional polymers can also be electrospun into matrices for drug delivery, tissue engineering, and other applications. For example, see Z. M. Huang, Y. Z. Zhang, M. K. Kotaki and S. Ramakrishna, Composites Sci. and Tech. 2005, 63, 2222-2233, (US Patent publication No. US20030137069).

Although there have been reports of the use of electrospun fibers as scaffolds for select drug delivery and biomaterials applications, the incorporation of bioactive molecules has not been widely exploited. In one example, tetracycline was included in a solution of poly(lactic acid) (PLLA) and poly (ethylene-co-vinyl acetate) and electrospun in a fiber membrane to study the release profile of the fiber-encapsulated drug. PLLA has also been studied as a matrix to incorporate the drugs rifampin (to treat tuberculosis) and paclitaxel (anti-cancer drug). Polymers loaded with both of these therapeutic molecules could be fabricated into nanometer to micron diameter electrospun PLLA fibers and used for delivery of the drug.

While the development of functionalized polymers that can elicit specific biological responses is of great interest in the biomedical community, as well as the development of methods to fabricate these biologically functionalized polymers, there is still a need for more facile methods to create biologically active functionalized matrices that permit immobilization and long-term delivery of biomolecules and other small functioning molecules, moieties, and/or particles.

For example, although there have been studies demonstrating the utility of functionalizing electrospun fibers, the functionalization of electrospun fibers to confer specific biological activity would be particularly advantageous for many biomaterial applications, as such modification would permit the fabrication of biomaterials that are structurally relevant and that possess properties designed to treat or address specific problems. In addition, such incorporation could serve to protect bioactive molecules, release them in relevant time-frame, and incorporate multiple such molecules. In particular, the development of simple methods to produce multifunctional electrospun fibers would advance the development of electrospun fibers for biomedical applications.

Of such bioactive molecules, glycosaminoglycans have been demonstrated to mediate a wide range of biological activities such as cell adhesion, cell mobility, cell proliferation and tissue morphogenesis via binding to various cell regulatory proteins such as the chemokines, growth factors, enzymes, enzyme inhibitors, and extracellular matrix proteins. The well studied glycosaminoglycan, heparin, is a linear, unbranched, highly sulfated polysaccharide chain, and it is well accepted that the electrostatic interactions between the sulfates of the glycosaminoglycan and basic residues of a protein play an important role in binding. In particular, the spatial orientation of the basic residues is a major determinant of heparin-binding ability, and variations in the pattern of the sulfation of the heterogeneous heparin therefore permit binding between heparin and a wide range of binding partners. Accordingly, heparin has been incorporated into covalent hydrogel delivery systems because of this ability to bind a diverse set of proteins. In addition, we and others have demonstrated that the interactions between heparin and specific HBP's can also mediate the assembly of noncovalently associated hydrogel networks (see, for example, N. Yamaguchi, K. L. Kiick, Polyaccharide-poly (ethylene glycol) star copolymers as scaffolds for the production of bioactive hydrogels, Biomacromolecules 6 (4) (2005) 1921-1930; N. Yamaguchi et al., Rheological characterization of polyaccharide-poly(ethylene glycol) star copolymer hydrogels, Biomacromolecules 6 (4) (2005) 1931-1940; B. L. Seal, A. Panitch, Physical polymer matrices based on affinity interactions between peptides and polyaccharides, Biomacromolecules 4 (6) (2003) 1572-1582).

Because hydrogels can mimic the high water content and mechanical properties of natural tissues, they are prime candidates as carriers of bioactive agents, in biodhesive systems, or as bioerogizable materials. Given that poly (ethylene glycol), or PEG, is highly hydrophilic and generally nonadhesive to proteins or cells, it has found widespread use as a drug carrier, and many PEG hydrogels have been produced from aqueous solutions containing linear or branched PEG macromolecules via chemical crosslinking. In addition to hydrogels formed via radical crosslinking reactions, PEG hydrogels have been formed, for example, via Michael-type addition reactions upon mixing with thiol-bearing compounds or via the reaction between amino-terminated poly (ethylene glycol) and the herbal iridoid glycoside genipin. In some cases, cell adhesive peptide domains or biodegradable sequences have been introduced into PEG hydrogels to endow them with more biological signaling functions, including the capacity for growth factor delivery. Accordingly, there have been a variety of covalently crosslinked hydrogel sys-
The present invention relates generally to a composition and method for the formation of functionalized polymer matrices comprising a matrix polymer, a compatibilizing polymer and a biomolecule or other small functionalizing compound, the polymer matrix comprising a growth factor, wherein growth factor release exhibits a controlled-release profile from the polymer matrix over at least seven days.

The invention is further directed to a functionalized polymeric matrix for the in vivo or in vitro delivery of a therapeutic compound, the polymer matrix comprising a growth factor, wherein growth factor release exhibits a controlled-release profile from the polymer matrix over at least seven days.

The invention is further directed to a functionalized polymer matrix comprising a matrix polymer, a compatibilizing polymer comprising PEG, and a small molecule comprising a biomolecule or other small functionalizing compound, the polymer matrix comprising a growth factor, wherein growth factor release exhibits a controlled-release profile from the polymer matrix over at least seven days.

Noncovalent interactions provide an alternative method for crosslinking, as introduced above, removing the need for toxic chemical crosslinking agents in gel preparation. In addition, noncovalent crosslinking strategies may offer advantages in maintaining protein integrity and bioactivity until delivery. Polymer hydrogels have been formed via specific recognition events such as reversible antibody-antigen interactions (see T. Miyata et al., *A reversibly antigen-responsive hydrogel*, Nature 399 (6738) (1999) 766-769) and coiled-coil interactions (see for example, C. Y. Xu et al., *Reversible hydrogels from self-assembling genetically engineered protein block copolymers*, Biomacromolecules 6 (3) (2005) 1739-1749; C. Wang et al., *Hybrid hydrogels assembled from synthetic polymers and coiled-coil protein domains*, Nature 397 (6718) (1999) 417-420; W. A. Petka, et al., *Reversibility of hydrogels from self-assembling artificial proteins*, Science 281 (5375) (1998) 389-392). There has been little attention given, however, to the interaction between peptides (particularly coiled-coils) and polysaccharides in hydrogel assembly. Further, the fabrication of biologically active fibers through such functionalization strategies is a fairly new and unexplored area in the field of electropinning, and electrosynthetic fibers have not been investigated for their ability to incorporate growth factor binding glycosaminoglycans, such as heparin, in a manner designed to control release.

**SUMMARY OF THE INVENTION**

The invention is directed to a functionalized polymer matrix for the in vitro or in vivo delivery of a therapeutic compound, the polymer matrix comprising a growth factor, wherein growth factor release exhibits a controlled-release profile from the polymer matrix over at least seven days.

The invention is further directed to a functionalized polymer matrix comprising a matrix polymer, a compatibilizing polymer comprising PEG, and a small molecule comprising a biomolecule or other small functionalizing compound, the polymer matrix comprising a growth factor, wherein growth factor release exhibits a controlled-release profile from the polymer matrix over at least seven days.

Noncovalent interactions provide an alternative method for crosslinking, as introduced above, removing the need for toxic chemical crosslinking agents in gel preparation. In addition, noncovalent crosslinking strategies may offer advantages in maintaining protein integrity and bioactivity until delivery. Polymer hydrogels have been formed via specific recognition events such as reversible antibody-antigen interactions (see T. Miyata et al., *A reversibly antigen-responsive hydrogel*, Nature 399 (6738) (1999) 766-769) and coiled-coil interactions (see for example, C. Y. Xu et al., *Reversible hydrogels from self-assembling genetically engineered protein block copolymers*, Biomacromolecules 6 (3) (2005) 1739-1749; C. Wang et al., *Hybrid hydrogels assembled from synthetic polymers and coiled-coil protein domains*, Nature 397 (6718) (1999) 417-420; W. A. Petka, et al., *Reversibility of hydrogels from self-assembling artificial proteins*, Science 281 (5375) (1998) 389-392). There has been little attention given, however, to the interaction between peptides (particularly coiled-coils) and polysaccharides in hydrogel assembly. Further, the fabrication of biologically active fibers through such functionalization strategies is a fairly new and unexplored area in the field of electropinning, and electrosynthetic fibers have not been investigated for their ability to incorporate growth factor binding glycosaminoglycans, such as heparin, in a manner designed to control release.

**BRIEF DESCRIPTION OF THE DRAWINGS**

**FIG. 1** is a scanning electron micrograph of PEO/LMWH-dye electrospun fibers.

**FIG. 2** shows Laser Scanning Confocal Microscopy (LSCM) images of electrospun PEO fibers (a) transmitted light and (b) fluorescence (5 µm scale bar).

**FIG. 3** is an LSCM image of electrospun PEO/LMWH-dye fibers (5 µm scale bar).

**FIG. 4** is a scanning electron micrograph of electrospun PEO/PEG-LMWH-dye fibers.

**FIG. 5** is an LSCM image of PEG-LMWH-dye/PEO electrospun fibers (5 µm scale bar). Dark and colored regions are caused by folds in the surface of the macroscopic sample; not by composition variations.

**FIG. 6** shows scanning electron micrographs of (a) PLGA electrospun fibers, (b) PLGA/LMWH-dye fibers, and (c) PLGA/PEG-LMWH-dye fibers.

**FIG. 7** shows LSCM images of electrospun PLGA fibers (a) transmitted light and (b) fluorescence (10 µm scale bars).

**FIG. 8** shows LSCM images of electrospun (a) LMWH-dye/PLGA fibers and (b) PEG-LMWH-dye/PLGA fibers and (c) z-stack of PEG-LMWH/PLGA fibers (10 µm scale bars).

**FIG. 9** shows bFGF binding on electrospun fibers. Each bar indicates ±standard deviation of the average of three measurements.

**FIG. 10** shows scanning electron microscopy images of PEG-LMWH-dye/PLGA fibers and LMWH-dye/PLGA fibers after incubation in PBS for 6 h, 1 day, 3 days, and 14 days.

**FIG. 11** shows retention of heparin within electrospun matrices as observed by multiphoton microscopy for the PEG-LMWH-dye/PLGA fibers and LMWH-dye/PLGA fibers after incubation in PBS for 6 h, 1 day, 3 days, and 14 days (10 µm scale bars).

**FIG. 12** shows retention of PEG-LMWH-dye within depth of the electrospun matrix after 14 days of incubation in PBS as imaged via multiphoton microscopy.

**FIG. 13** depicts the release of bFGF from PLGA, LMWH-Dye, and PEG-LMWH-Dye electrospun fibers after 5 h and 24 h incubation in PBS.

**FIG. 14** is a digital picture displaying the visual differences observed in the binding of bFGF to PLGA, LMWH-Dye, and PEG-LMWH-Dye electrospun fibers after 5 h and 24 h incubation in PBS.

**FIG. 15** shows the results from the BrdU cell proliferation assay. Each bar indicates ±standard deviation of the average of three measurements.

**FIG. 16** provides LSCM images of (a) LMWH/PLGA and (b) PEG-LMWH/PLGA fibers (blue) incubated for 8 days with MG63 cells (green) (10 µm scale bars).

**FIG. 17** shows (a) CD spectra of PEG-PF4ZIP at different concentrations in PBS at 25° C.; (b) Concentration dependence of the MRE for PEG-PF4ZIP at 222 nm. The solid line is the best fit.

**FIG. 18** is a schematic of the assembly of hydrogels from solutions of the two polymer conjugates. The PF4ZIP is rendered as an oligomerized coiled-coil, as its concentration (200 µM) under these experimental conditions is two orders of magnitude greater than the measured Kd value.

**FIG. 19** depicts storage moduli (closed symbols) and loss moduli (open symbols) of the PEG-LMWH/PEG-PF4ZIP hydrogels for different molar ratios. The response of 2.5 wt% A) of the PEG-LMWH (circles) is shown for comparison.

**FIG. 20** shows plots of normalized storage moduli G' (ω=0.1 Hz) as a function of HIP (PF4ZIP, ATIII or HIPP) to LMWH. HIP and ATIII data are adapted from reference 12.

**FIG. 21** is a comparison of storage moduli (closed symbols) and loss moduli (open symbols) of the PEG-LMWH/PEG-PF4ZIP hydrogels (LMWH:PF4ZIP=9:0.5) obtained at 25° C. and 37° C.

**FIG. 22** shows shear recovery data for PEG-LMWH/PEG-PF4ZIP hydrogels (LMWH:PF4ZIP=9:0.5) at 25° C. and 37° C.

**FIG. 23** depicts the bFGF release and hydrogel erosion profiles of the PEG-LMWH/PEG-PF4ZIP hydrogel (LMWH:PF4ZIP=8:1) and the PEG-LMWH/PEG-HIP hydrogel (LMWH:HIP=8:2). The errors are derived from the average of at least duplicate measurements.

**FIG. 24** shows graphs of the release of growth factors from electrospun materials. (a) PDGF release from PLGA-based materials; (b) VEGF release from PU-based materials, (c) FGF release from collagen-based materials.

**DETAILED DESCRIPTION OF THE INVENTION**

The present invention relates generally to a composition and method for the formation of functionalized polymer matrices comprising a matrix polymer, a compatibilizing polymer and a biomolecule or other small functionalizing
molecule. The invention is a novel strategy for the incorpo-
ration of low molecular weight, biologically active molecules 
(or molecules with other activities, e.g. sugars, peptides, 
polysaccharides, polypeptides, dyes, electroactive groups, 
etc.) into a fibrous or other matrix. The biological (or other) 
molecules are conjugated to an intermediate molecular 
weight polymer or "compatibilizing polymer" (e.g., but not 
limited to: linear, star, hyperbranched) to allow retention of 
the biomolecule in its bioactive form in fibers and other forms 
of polymeric materials (e.g. films, gels, solids, particles, etc.). 
Facile functionalization of electrospun fibers and other ma-
terials with other low molecular weight, bioactive polysac-
charides and peptides (and other molecules) is contemplated 
by this invention. Such functionalization is important because 
biological processes are controlled via multiple and different 
signaling molecules that have distinct spatial and temporal 
release profiles, and the rate of their release from the fibers 
can be controlled with the technology of this invention.

The invention is currently demonstrated in a preferred 
embodiment comprising a low-molecular-weight-heparin 
(LMWH)-modified star copolymer incorporated into elec-
trospun fibers. Attachment of active molecules to intermediate 
molecular weight polymers provides effective retention of the 
molecules in the material over time scales relevant for bio-
logical and other potential applications. The choice of inter-
mediate molecular weight compatibilizing polymer will per-
mit control over retention and release rate of the molecule 
or other active species.

Advantages of using a polymer-conjugated biomolecule 
(i.e. polymer conjugate) for incorporation of bioactive moi-
eties into materials as provided by the invention, in place of 
covalent attachment of the biomolecule to a high molecular 
weight polymer used directly in material formation, are sev-
eral-fold. For instance, they include i) the use of a polymer 
conjugate of the invention does not require a need for the 
development of distinct chemistry relevant for a particular 
molecule/polymer pair used in the material, as any polymer 
conjugate could be incorporated into any polymeric matrix; 
ii) the use of a polymer conjugate of the invention does not 
limit the number of molecules that could be incorporated into 
given a material for a given set of chemical transformations; 
iii) in biological applications, the incorporation of biomol-
eecules via the current invention permits their controlled 
release in soluble form; iv) it is easier to control release rate 
and inclusion of multiple molecules at varying ratios/ 
amounts than when a bio (or other) molecule must be 
covalently attached directly to the polymers of the material; 
and v) the incorporation of biomolecules into materials via 
this invention allows not only control over release rates, but 
permits facile incorporation of multiple biological (or other 
avtive) species into materials, and offers the potential for each 
species to have a separate and distinct release rate.

The materials may find application in drug delivery or 
tissue engineering scaffolds to promote tissue repair and/or 
regeneration. They could be useful in other materials in 
related applications where controlled release of a multiple 
of active ingredients is desired, e.g. biosensors, detoxification, 
DNA delivery, etc.

An important, overriding difference of the invention from 
the prior art is that it allows for molecules (e.g. growth factors, 
proteins, peptides, and other non-biological molecules, etc.) 
to be incorporated into a polymer matrix via compatibiliza-
tion of the molecules with the polymer matrix, and that it 
further allows for the controlled incorporation and release of 
a variety of different molecules from a polymeric matrix. For 
example, in the preferred embodiment (described in more 
detail in example 1), the incorporation of heparin, and more 
preferably LMWH, into an electropun matrix via its attach-
ment to a star PEG polymer provides increased growth factor 
binding to the electropun matrix. The increased growth fac-
tor binding is due to the conjugation of LMWH to the PEG 
molecule. The PEG-LMWH molecule takes longer to diffuse 
out of the matrix, therefore allowing for more growth factor 
binding to occur within a given time period as shown by 
comparing the amount of growth factor binding to the PEG-
LMWH matrix versus a matrix consisting of LMWH alone 
(See Example 1).

In the case of electropun matrices, while there are limita-
tions to what polymers can be electropun, there are many 
possible uses. Solubility of fibers must be controlled, but such 
control is also possible with this invention as well as matching 
of mechanical properties for specific applications that are 
accomplished using appropriate choice of polymer, additives, 
and/or processing protocols.

Matrix Polymer

Matrix polymers, effective in this invention include but are 
not limited to: Nylon 6,6; Nylon 6,10; (other nylons, also), 
polyurethanes, polycyacylonitrile, polyvinyl alcohol, polyla-
tic acid, polyethylene-co-vinyl acetate, polycarbonate, poly 
(iminoacarbonate), polymethacrylates, poly(alkyl meth-
crylic acid)s, polyacrylates, poly(alkyl acryl acid)s, poly 
(N,N'-diethyldiaminoethyl methacrylate), poly(N,N'--
dialklylaminoalkyl acrylamides), poly(ethylene oxide)/PEO, 
polyethylene terephthalate, polystyrene, polyvinyl chloride, 
vinyl phenol, polyacrylamide, poly(N-alkyl acrylamide) 
s, poly lactic-co-glycolic acids, polycaprolactone, poly(2-
hydroxyethyl methacrylate) (polyHEMA), poly(vinylidene 
fluoride), poly(vinylidene chloride), poly(ethylene glycol)/ 
PGE, polyvinyl pyrrolidone, polyethylene, polypropylene, 
poly(3-hydroxybutytrate), poly(ortho esters), polyanhdy-
drides, poly(ether-ester) azopolymers, poly(dimethyl silox-
ane), poly(phosphazenes), other copolymers of the above 
homopolymers (e.g. poly(methacrylic acid-co-ethylene gly-
col), and others.

Matrix polymers may also comprise natural polymers, 
such as collagen, silk, silk-like protein polymers, elastin, 
estatin-like protein polymers, poly(amino acids), cellulose 
acetate, hyaluronic acid, chitosan, fibronectin, and others.

Combination fibers comprising mixtures of different syn-
thetic and/or natural polymers can also be prepared. Polymer 
combinations help to optimize solubility and mechanical 
properties of the fibers.

Composite materials comprising any of the above poly-
mers and an appropriate inorganic matrix (clays, silicates, 
microparticles, etc.) can also be employed as a matrix poly-
mer for applications requiring high mechanical strength, such 
as hard tissue engineering applications.

For drug delivery and biological applications, the follow-
ning are particularly preferred: Poly(ethylene), poly(propyl-
ylene), poly(vinyl chloride), poly(vinyl alcohol), poly(ethyl-
eneyl-vinyl acetate), poly(enol-ketone), poly(acrylic acids), 
poly(acrylamides), poly(N-alkyl acrylamides), poly(alkyl 
acrylates), PEG, PEO, poly(tetrafluoroethylene), poly(gly-
colic acid), poly(lactic acid), poly(lactic-co-glycolic acid), 
poly(caprolactone), poly(3-hydroxybutyrate), poly(ortho 
esters), poly(anhydrides), poly(amido amines), poly(ure-
thanes), poly(dimethyl siloxane), poly(phosphazenes), 
among others. In addition, collagen, silk, silk-like protein 
polymers, elastin, elastin-like protein polymers, poly(amino 
acids), cellulose acetate, hyaluronic acid, chitosan, fibronect-
in, and others, may also be used.

For applications in which a molecule is to be released in a 
non-biological environment (e.g., water purification, agricul-
tural treatments, biosensors, smart fabrics, etc.), any of the
above polymers could be employed; specific polymers would be chosen on the basis of the specific application.

Compatibilizing Polymer

Any moderate molecular weight polymer, of the chemical compositions of the above matrix polymers, that can be modified to the large degree of segmental flexibility in aqueous solution and it is thought that PEG has the ability to influence the structure of several molecular layers of more loosely associated hydrated water molecules.

PEG is valued for its ability to exclude other polymers (natural and synthetic) from its presence in aqueous environment. This exclusion of other polymers is the primary driving force behind PEG’s ability to reject proteins, from two-phase systems with other synthetic polymers, and makes this polymer both nonimmunogenic and nonantigenic. Because of its many benefits, PEG is ideally suited for protein modification. Indeed, PEG is currently considered one of the most successful techniques to prolong the residence time of protein drugs in the bloodstream. There are dozens of examples of PEG-protein conjugates described in the literature. For example, PEG has been considered a tool to enhance drug delivery to neoplastic tissues such as, for instance, pegylated proteins that have been applied in passive tumor-targeting while pegylated monoclonal antibodies or MoAb fragments have been investigated as immunotargeting agents.

PEG conjugation technology has been used, for example, to improve the therapeutic efficacy of recombinant human proteins because it alleviates many problems associated with therapeutic protein formulations. For example, the attachment of PEG to a protein affects its molecular size, charge, receptor-binding capabilities, which can serve to decrease the conjugate’s overall rate of clearance from the body. Also, by sterically shielding the protein domains susceptible to proteolytic attack, PEG decreases the protein degradation that causes protein biological inactivity. Finally, by sterically masking a therapeutic protein’s immunogenic/antigenic determinants, PEG conjugation commonly results in conjugates that are nonimmunogenic and nonantigenic. The result of changes in the parental protein’s characteristics by PEG almost invariably increases the plasma half-life and resistance to proteolytic degradation, and decreases immunogenicity and antigenicity of the resultant PEG-protein conjugate. Although PEG is generally considered to be non-immunogenic, its parenteral administration has been found to stimulate the production of antibodies.

Small Functioning Molecule

Small functioning molecules according to this invention include, but are not limited to, biomolecules and functional molecules such as peptides, sulfated peptides/polypeptides, peptides/polypeptides with other functionalization/modifications, peptides/polypeptides containing non-natural amino acids, polypeptides (natural AA, sulfated, non-natural AA, other modified side chains, etc.), protein fragments, proteins (e.g., growth factors, growth hormones, cytokines, insulin, etc.), enzymes, saccharides, oligosaccharides, polysaccharides, small molecule drugs (e.g., doxorubicin, aspirin, adriamycin, tetracycline (antibiotic), chloroquine (antimalarial), tamoxifen, and other small molecule drugs that can be chemically conjugated to a polymer), dyes, organics, metals, and nanoparticles and nanomolecules.
One particularly interesting biomolecule is heparin. Heparin is a highly sulfated glycosaminoglycan that binds growth factors such as fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), heparin-binding epidermal growth factor (HB-EGF), transforming growth factor-β (TGF-β), and others. Those having skill in the art are clearly aware that growth factors are important for controlling cellular activities such as cell growth and proliferation. The incorporation of heparin in the electrospun matrix is of functional importance owing to heparin’s role as a binding site for many growth factors; sulfated peptides may have similar activity and would therefore also be useful for similar reasons. For example, the binding of growth factors to glycosaminoglycans in the ECM is essential for storage, release, and preserv-ation of the bioactivity of the growth factor. Heparin primarily serves to immobilize growth factors until release but is also known to control their mitogenic activity, and in several cases, serves as a cofactor to promote binding of the growth factors to their receptors. Heparin is also known to regulate the growth of fibroblast and endothelial cells when combined with heparin-binding growth factors. For example, heparin has been reported to have been incorporated into a chitosan hydrogel where it was found to induce neovascularization in vivo and enhanced the activity of acidic fibroblast growth factor (aFGF) and basic fibroblast growth factor (bFGF) and stabilized the growth factors in vitro. A variety of other reports also confirm the benefits of including heparin in a bulk hydrogel matrices, such as those comprising fibrin, PEG, collagen, hyaluronic acid, and synthetic polymers, and the extension to a fibrous matrix may provide additional structural advantages for producing materials that mimic the ECM. Incorporation of biomolecules such as heparin, into a polymer matrix allows for the exploitation of heparin’s affinity for growth factors as a strategy to deliver them from a fibrous ECM-mimetic matrix. Those having skill in the art understand that heparin binds a variety of proteins with disparate function. It is contemplated that any such protein would be a candidate for use in this invention.

Method of Formulating Functionalized Polymers

Some methods for processing polymers into a given form that can be applied in the invention for producing polymeric matrices capable of controlled release of the compatibilizing polymer/biomolecule conjugates include, for example, crosslinking of a polymer to form a hydrogel network can be employed; any method for crosslinking polymers can be applied for formation of the crosslinked network, using standard initiators or at least trifunctional monomers; standard free radical initiators include thermal initiators, redox initiators, photoinitiators; the inclusion of a bifunctional vinyl monomer with appropriate vinyl monomers would produce crosslinked networks of the vinyl matrix polymers. Additionally, non-covalent methods of producing a crosslinked network could be employed. Such interactions include but are not limited to ionic crosslinking (e.g. alginate crosslinking via interaction with divalent cations, layer-by-layer deposition of polyelectrolytes, etc.), protein-protein interactions, peptide-saccharide interactions, saccharide-saccharide interactions, self-assembly of peptic molecules, and antibody-antigen interactions. The pore size of the crosslinked network should be smaller than the size of the compatibilizing polymer/biomolecule conjugate in order to permit release of the biomolecule to be delayed via its conjugation to the compatibilizing polymer.

Any method of forming different three-dimensional particles and structures could also be applied in the current invention. For example, emulsion (or inverse emulsion) polymerizations, crosslinking (in colloidal suspensions, micellar or liposomal solutions, or emulsions), or spray crosslinking can be used to form particulate and nanoparticulate polymers. Crosslinking of monomer solutions in a mold or microfluidic channel permits the construction of a matrix of essentially any shape/size. Films cast of the monomer solutions (e.g., via spincoating, doctor blade application, dipcoating, etc.) can also be produced via crosslinking by any of the above mechanisms or via simple casting/drying of a non-water soluble polymer.

Electrostatic fiber spinning, or “electrospinning,” is a preferred process for this invention. Electrospinning is a process by which superfine fibers, ranging from approximately 10 nanometers to about 1 micron in diameter, are formed. The resulting electrospun fiber web has a high specific surface area that is beneficial in a wide variety of technologies due to the small fiber diameter and its porous structure. A high voltage source is used during the electrospinning process to generate an electrically charged jet of polymer solution or melt expelled from a device such as a pipette. This process is then followed by a drawing of the resulting filaments as they solidify or coagulate. Electrospinning provides a simple approach for production of solid, as well as hollow, one-dimensional nanofibers from a variety of starting materials. To date, dozens of synthetic or natural polymers, melts, and polymer blends have been successfully spun using the electrospinning process. (see, for example, Shin et al., Biomaterials 2003, 24, 4353-4364; Sakagami et al., Polymer 2003, 44, 5721-5727 (Frank Ko); Li et al., J. Biomed. Mater. Res. 2002, 60, 613-621 (Frank Ko); Jin et al., Biomacromolecules 2002, 3, 1233-1239 (David Kaplan); Jin et al., Biomaterials, 2004, 25, 1039-1047 (David Kaplan); Farnath-Carson, M. C.; Wagner, R. C.; Kiick, K. L., Extracellular Matrix: Structure, Function, and Applications to Tissue Engineering, CRC Biomedical Engineering Handbook, CRC Press, New York, 2004; Huang et al., Composites Science and Technology 2003, 63, 2223-2235) (All said references are herein incorporated by reference in their entirety). A broad range of electrospun material has been published and include synthetic polymers with electrical properties ranging from non-conducting polyurethane to conducting polyaniline, in addition to natural polymers such as collagen and silkworm silk. There is also much recent work on nanofibers electrospun from biocompatible or biodegradable polymers for biengineering applications. The fibers may be made from a polymer solution via an electro spinning process as described in Reneker, U.S. Pat. No. 4,323,525, U.S. Pat. No. 4,689,525, US 20030195611, US 20040018226, and US 20010045547, which are incorporated herein by reference in their entirety. The specific types of polymers that may be produced in fiber form via the electrospinning process include those listed in Huang, US 20030195611, US 20040037813, US 20040038014, US 20040018226, US20040013873, US 2003021792, US 20030215624, US 20030195611, US 20030168756, US 2003016294, US 20020175449, US20020100725 and US20020084178 all of which are herein incorporated by reference in their entirety.

When constructing electrospun fibers for biomedical applications, certain material considerations must be acknowledged. Some minimal properties of a drug delivery system are that the material must be non-immunogenic, degradable with non-toxic products, able to be excreted from the body, and deliver therapeutic molecules in a controlled and predictable manner. Manufacturing time and complexity, along with handling, must also be considered. In compliance with these requirements, matrix polymers such as PEO and PLGA serve as excellent candidates for fabrication of the matrix via electrospinning; indeed, the successful use of these polymers in a
variety of tissue engineering and drug delivery applications has been documented. Those having skill in the art are familiar with the processes used in tissue engineering and drug delivery as required for incorporation in this invention.

In addition to electrospinning, other traditional methods of making polymeric fibers can be applied, when possible, to the formation of active fibers of larger diameter. Given the choice of biomolecule or functional molecule or particle with a particular matrix polymer would dictate the use of solution spinning, melt spinning, or other spinning protocols.

Regarding the attachment of the biomolecule (or other small functioning molecules) to the compatibilizing polymer, the chemical reactions to be used are unlimited and are chosen based on the desired compatibilizing polymer/biomolecule combination. Initially, the matrix polymer composition may be altered for any given desired application and the combinations of matrix polymer/compatibilizing polymer/biomolecule for any application are limited only by the choice of a given application, not by the scope of the invention.

In a preferred embodiment, poly(ethylene glycol) (PEG) functionalized with low molecular weight heparin (PEG-LMWH), is fabricated into fibers for use in drug delivery, tissue engineering, or wound repair applications. In particular, a four-arm star PEG with covalently attached LMWH was found to be well suited for incorporation into electrospun fibers with matrix polymers such as PEO and PLGA. Further, the use of a PEG-LMWH conjugate proved to have a better effect on growth factor binding than when compared to free LMWH (see Example 1).

Interestingly, it was observed that the incorporation of heparin into the electrospun PEO and PLGA fibers did not affect the surface morphology or fiber diameters. The fibers produced had diameters ranging from approximately 100 nm to 400 nm. Our data indicates that PEG-LMWH conjugates can be incorporated into an electrospun matrix at concentrations ranging from 3.5 µg to 85 µg per milligram of electrospun fibers, although with greater heparin concentrations in the spinning solution, it should be feasible to produce higher levels of heparin loading in the fibers. Incorporation of PEG-LMWH into the matrix permits retention of the heparin for at least 14 days. Improvements in the binding of basic fibroblast growth factor (bFGF) to the electrospun fibers were also observed for fibers functionalized with PEG-LMWH over those functionalized with LMWH alone. The combination of these results suggests the utility for producing electrospun fibers that are appropriately functionalized for use in biomaterials applications. Although LMWH was indicated to be incorporated into fibers with simple mixing in our investigation, the conjugation of LMWH to the star PEG slightly improved the amount of heparin incorporated into the fiber matrix and permitted a significantly improved amount of growth factor binding to these matrices, which was suggested to result from an improved retention of heparin in the fibers. If the use of such PEG-LMWH conjugates also slows the release of heparin over extended periods of time, it will allow for a slower, more sustained release of growth factor, which is often required to achieve desired biological outcomes.

The conjugation of heparin, and more preferably, LMWH, to a relatively short (relative to the matrix polymer molecular weight) polymeric chain therefore permits facile functionalization of fibers and also allows for retention and significantly slowed release of LMWH from the matrix over time. Given the importance of co-presentation of the LMWH with growth factors at the growth factor receptor these systems also offer the potential advantage of improving growth factor activity over systems in which heparin is covalently attached directly to the matrix and can therefore not be co-released with growth factor. The rate of release of heparin (and therefore growth factors) may also be modified via modifications in the polymer conjugate’s molecular weight over a wide range, and coupled with the greater entanglement likely for flexible polymer chains, this may offer advantages over simple incorporation of a higher molecular weight heparin in fibers. In addition, the controlled incorporation and delivery of other and potentially smaller bioactive molecules, such as peptides, would also be widely possible via the incorporation of other similar PEG bioconjugates into these fibers. The ability to simply mix various PEG-conjugates in the electrospinning solution also offers advantages for creating multifunctional fibers.

The PEG-LMWH molecules used in these electrospinning studies have previously been demonstrated to be capable of sequestering growth factors in hydrogels in a bioactive form to induce proliferation of human umbilical vein endothelial cells. The amount of LMWH in these electrospun fiber matrices (3-86 µg) is also similar to that in hydrogels produced with these polymers; the hydrogels can effectively release bFGF for time periods of at least 16 days. These results therefore show significant promise for the potential of delivering similar active growth factors from electrospun matrices. The additional advantage of the ease of mixing combinations of PEG-conjugates in the fibers is also promising for the facile production of multifunctional, non-immunogenic matrices for biomaterial applications.

It was found that LMWH functionalized PEG molecules can be easily incorporated into electrospun fibers. These fibers have nanometer scale diameters when electrospun using either PEO or PLGA as carrier polymers. The amount of LMWH per mg of fibers can range from 3.5-9.5 µg depending on the sample examined. Although both LMWH and PEG-LMWH can be processed into fibers, the incorporation of PEG-LMWH results in functional advantages such as improved growth factor binding, resulting from improvements in retention of the PEG-LMWH in the fibers over the LMWH alone. The PEG-LMWH can be retained in the fibers for at least 14 days, in contrast to LMWH, which is almost completely released from the fibers after 24 hours. A slower release of LMWH, and any coupled growth factors, allows for drug delivery over a period of time that more closely matches the time scales needed for tissue repair or regeneration should the fibers be used in biomedical applications. The use of electrospinning as the fabrication method for this biologically functionalized matrix is preferred due to its ability to allow for the incorporation of LMWH, ease of fabrication, fiber spinning at a variety of temperatures, and use of small amounts of material. The ability to scale electrospinning from the laboratory to the industrial scale offers opportunities to produce matrices for biomaterials applications. The electrospun matrix also meets many requirements in its porosity and 3-D nature to make the fibers suitable for drug targeting and tissue engineering applications. Such simple strategies for creating electrospun matrices that are both structurally relevant and biologically active could find increased utility in a variety of biomedical applications.

Functionalized Cross-Linked Matrices

In an alternative embodiment, the invention is directed to the use of a functionalized compatibilizing polymer in the production of materials in which assembly, mechanical response, and biological properties are controlled by protein-polysaccharide interactions. Such materials are designed to mimic the biological environment and find use in the delivery of growth factors.
Specifically, functionalized crosslinked matrices, such as hydrogels, capable of assembly by, for example, interactions between heparin and peptides, permit the formation of matrices that allow for effective protein delivery. For example, an elastic or viscoelastic hydrogel formed by the combination of a compatibilizing polymer-LMWH conjugate and a compatibilizing polymer-peptide conjugate is a preferred interaction contemplated herein. While the use of any compatibilizing polymer is contemplated, a preferred compatibilizing polymer for use in this embodiment would include PEG. Also, while preferred, it is not necessary that the compatibilizing polymer be the same for both the LMWH conjugate and the peptide conjugate.

In this particular embodiment, a hydrogel provides the benefits of controlling drug delivery rates by, for example, changing the heparin-binding peptide or manipulating the hydrogel’s physical properties and erosion profiles. In a specifically preferred embodiment (more fully described in Example 4) a heparin-binding, coiled coil peptide, PF-ZIP, was employed to mediate the assembly of heparin and peptides. Heparin binding peptides (HBP) from antithrombin III and the heparin interacting protein have also been employed; any heparin-binding peptide with desired affinities can be used in the production of materials of this kind. Importantly, viscoelastic hydrogels were formed upon the association of PF-ZIP-functionalized star poly(ethylene glycol) (PEG-PF-ZIP) with low-molecular-weight heparin-functionalized star PEG (PEG-LMW). The viscoelastic properties of the hydrogels can be altered via variations in the ratio of LMWH to PF-ZIP (or any HBP). Comparison of growth factor (bFGF) release profiles with the hydrogel erosion profiles indicates that bFGF delivery from this class of hydrogels is mainly an erosion-controlled process and the rates of bFGF release can be modulated via choice of HBP or via variations in the mechanical properties of the hydrogels. Manipulation of hydrogel physical properties and erosion profiles provides novel materials for controlled growth factor delivery and other biomedical applications.

Growth Factor-Cross-Linked Matrices

In even another alternative embodiment, the invention is directed to the use of a functionalized compatibilizing polymer to form a crosslinked matrix that comprises the combination of a compatibilizing polymer-biomolecule conjugate and a growth factor, wherein a biomolecule such as LMWH functions effectively. In such an embodiment, it is intended that the growth factor function as a cross-link that eventually is removed and drug is released. Removal of the growth factor may result from passive release and/or targeted release via targeted ligand exchange of the growth factor with specific receptors on cell surfaces. The growth factor crosslink may also itself be the desired drug, or in certain cases, the PEG-LMWH polymer may have desired biological effects.

In a specifically preferred embodiment, PEG-LMW can be mixed with vascular endothelial growth factor (VEGF) to form a viscoelastic hydrogel. Formation of a hydrogel occurs as a result of the binding of the heparin-binding VEGF, with multiple heparin binding sites, to the PEG-LMW. While VEGF, a dimeric growth factor with two heparin-binding sites, is described, other methods for generating growth factors with multiple heparin binding sites could produce a growth factor capable of crosslinking PEG-LMW polymers via noncovalent interactions (e.g. genetic mutation of growth factor genes to introduce additional heparin-binding sites in the growth factor, conjugation of multiple growth factors to a polymer, etc.). Noncovalently crosslinked PEG-LMW/VEGF hydrogels are capable of releasing VEGF over periods spanning at least two weeks, and the release of VEGF (and resulting erosion of the network) is also responsive to the presence of the cell surface receptors for VEGF. Release of VEGF, and erosion of the network, can therefore be coupled and made responsive to the cellular environment. VEGF released from such assemblies causes increased proliferation of porcine aortic endothelial (PAE) cells, which confirms that the released VEGF is bioactive. Release of other growth factors via similar mechanisms should therefore also be possible to permit release of multiple, bioactive growth factors.

Although the invention is illustrated and described herein with reference to specific embodiments, the invention is not intended to be limited to the details shown. Rather, various modifications may be made in the details within the scope and range of equivalents of the claims and without departing from the invention.

EXAMPLES

Electrospinning Functionalized Fibers

Materials and Methods

Hydroxy terminated and thiol terminated four-arm star poly(ethylene glycol)s (Mn = 10,300; Mw = 11,300 g/mol and Mw = 10,000; Mw = 10,800 g/mol, respectively) were purchased from Polymer Source (Dorval, QC, Canada). LMWH sodium salt (porcine intestinal mucosa, avg. molecular weight 3000 g/mol) was obtained from Sigma (St. Louis, Mo.). Alexa Fluor® 350 carboxylic acid, succinimidyl ester was obtained from Molecular Probes (Eugene, Oreg.). Solvents and reagents were distilled or purified according to standard procedures.

Synthesis of PEG-LMW Conjugate

N-Deacetylation of LMWH

LMWH (Mn = 3000 g/mol) was used in these investigations. In some cases, the LMWH was first separated into a high affinity fraction via anionic exchange chromatography on diethyl aminomethyl (DEAE) resin. Such fractionation is not an absolute requirement, but provides a LMWH fraction with higher heparin binding affinity. LMWH was eluted from the column via gradient elution in Tris buffer (pH 7.5, 20 mM) with sodium chloride concentrations ranging from 0 to 2M. The late eluting fraction of LMWH was collected, dialyzed against several changes of deionized water (SpectraPor, MWCO 1000 Da), and lyophilized prior to use. The fractionated LMWH (250 mg), hydrazine (5.3 g), hydrazine sulfate (53 mg), and water (2.3 mL) were added to a heavy duty reaction vessel, and the reaction vessel was tightly capped and the mixture was stirred at 95°C for 16 h. After the solvents were removed in vacuo, the product was dried using a SpectraPor dialysis membrane (MWCO 1000 Da) first against 1 M NaCl and finally against water (for each dialysis bath was changed four times after 2, 8, 16, and 24 h) and lyophilized to afford a slightly yellowish solid, 153 mg (61% yield).

Synthesis of Maleimide and Alexa Fluor 350® Functionalized LMWH

To a 10 mL vial were added N-deacetylated heparin (10 mg), dry Dowex 50WX4-200 ion-exchange resin (strongly acidic cation), and anhydrous dimethylformamide (DMF, 4 mL) and the reaction mixture was stirred at room temperature until complete dissolution of heparin was observed. The resin was filtered and to the filtrate were added a few drops of anhydrous triethylamine and a solution of 4-(N-maleimidomethyl)cyclohexanecarboxylic acid N-hydroxysuccinimide ester (0.75 equiv.) (Sigma, St. Louis, Mo.) in anhydrous DMF.
(0.3 mL) and the reaction mixture was stirred at 60°C for 20 h. This mixture was added to a solution of Alexa Fluor 350-labeled carboxylic acid, succinimidyl ester (1 equiv.) in anhydrous DMF and the reaction mixture was further stirred at 60°C for 20 h. The solvent was removed in vacuo to give a slightly yellowish solid, which was dissolved in PBS (pH 6.5, 0.1 M, 0.15 M NaCl). After the insoluble particles were filtered, the filtrate was purified via fast protein liquid chromatography (FPLC) equipped with a Superdex 200 gel filtration column (Amersham, Piscataway, N.J.) using 0.2 M NaCl at 0.5 mL/min as eluting buffer. The heparin containing fractions were combined and dialyzed using a SpectraPor membrane (MWCO 1000 Da) with 1 M NaCl and finally with water (each dialysis bath was changed four times after 2, 8, 16, and 24 h) and were then lyophilized to give a slightly yellowish solid, 4.2 mg; 1H NMR (400 MHz, D2O, 29°C): δ 0.86-1.95 (10H, cyclohexyl, m), 3.38-5.43 (28H, heparin, m), and 6.84 ppm (2H, -COCH2CHO-). Synthesis of PEG-LMWH.

To a 100 mL round bottom flask equipped with a N2 inlet were added maleimide and dye-functionalized LMWH (120 mg) and PBS (10 mL, pH 6.5, 0.1 M, 0.15 M NaCl) and the solution was degassed by bubbling N2 for 15 min. 25 This solution was slowly added a degassed solution of PBS containing thiol terminated four-arm star PEG (65 mg in 10 mL) and the reaction mixture was stirred at room temperature for 2 h. The reaction of the thiol was 96% complete as confirmed via analysis with Ellman’s reagent. The reaction mixture was quenched by adding a solution of N-ethylmaleimide (12 mg) in DMF (0.4 mL). The crude product was purified via FPLC with a Superdex 200 gel filtration column (Amersham, Piscataway, N.J.) at 0.5 mL/min using 0.2 M NaCl as eluting buffer. The product isolated by FPLC was purified via dialysis against water (water bath was changed four times after 2, 8, 16, and 24 h) and lyophilized to give a slightly yellowish solid, 150 mg; 1H NMR (400 MHz, D2O, 29°C): δ 0.86-1.95 (40H, cyclohexyl, m), 2.50-2.88 (12H, -COCH2CHO-), 3.38-5.43 (28H, heparin, m), and 3.70 ppm (908H, PEG backbone, -CH2CH2O-). Integration of the 1H NMR spectrum suggests 73% functionalization of PEG with LMWH.

Electrospinning and Characterization

The electrospinning apparatus consisted of a syringe pump (Orion Sage™, Fisher, Fair Lawn, N.J.), high voltage supply (Glassman Series EH, High Bridge, N.J.), 1 mL syringe (Popper & Sons, New Hyde Park, N.Y.) and a needle (Hamilton, Reno, Nev.) with an inner diameter of 0.51 mm. A voltage of 12 kV was applied to the tip of the needle. A grounded metal sheet was used as the target and was positioned 15 cm from the tip of the needle for sample collection. The concentration of the polymeric solutions varied depending on the carrier polymer employed. PEO (HDH Chemicals, Poole, UK, Mw~300,000 g/mol) was used at a 10 wt % concentration in water and a flow rate of 0.07 mL/min was employed. PLGA (Sigma Aldrich, St. Louis, Mo., 75:25, Mw~90,000-126,000 g/mol) solutions were made at a 45 wt % concentration in DMF (Fisher, Fair Lawn, N.J.) and required a flow rate of 0.26 mL/hr.

Characterization

The electrospinning fibers were characterized via field emission scanning electron microscopy (FESEM) (Hitachi S-4700) coupled with the energy dispersive X-ray (EDX) (Oxford Inca X-Ray Microanalysis) for elemental analysis of electrospun fibers. Laser scanning confocal microscopy, I.SCM, (Zeiss LSM 510 NLO) was used to observe the location of the heparin-bound dye. A fluorescence excitation wavelength of 747 nm and a KP685 filter were employed for these experiments. An oil immersion type Plan-Neofluar 40x/1.3 oil DIC (differential interference contrast) was used to obtain images in FIOS. 4, 5, 9, 10, 12 and a Plan-Apochromat 63x/1.4 oil Ph3 (phase contrast—the 3 denotes a specific condenser, lens used) was used to collect the image in FIG. 7. A 64-bit version was made for each sample at 0.8 or 1.0 μm sections.

Toluidine Blue Assays

To determine the amount of heparin in the electrospun fibers, a common colorimetric method employing toluidine blue was used. A toluidine blue solution was made by dissolving 25 mg toluidine blue (Sigma Aldrich, St. Louis, Mo.) and 1 g NaCl in 0.49 mL of 37% HCl and 50 mL of water. The toluidine blue that reacts with the heparin is removed from solution via extraction with hexanes (5 mL). The amount of unextracted toluidine blue remaining in the aqueous solution was determined by measuring the absorbance at 631 nm and, by difference, provides an estimate of the heparin concentration.

Samples were prepared by adding 1 mg of electrospun fibers to a solution consisting of 0.8 mL of toluidine blue solution and 2.5 mL of 0.1% NaCl. The test tube was vortexed and 5 mL of hexanes was added with additional vortexing. After 10 minutes, 1201 μL of the toluidine blue solution was transferred into a cuvette and absorbance measurements were taken. The control samples consisted of 1 mg of either PEO or PLGA fibers, without heparin, to adjust for the amount of toluidine blue that may adhere to the fibers. Measurements were performed in duplicate.

Growth Factor Binding

Growth factor binding assays were employed to determine if the LMWH and PEG-LMWH electrospun samples were able to bind bFGF. All growth factor experiments were completed at room temperature in 24-well polystyrene assay plates (Corning Inc., Corning, N.Y.), blocked with 3% bovine serum albumin (BSA) (Sigma Aldrich, St. Louis, Mo.) in phosphate buffered saline (PBS) (Inviagen, Carlsbad, Calif.). All electrospun samples were washed with PBS at room temperature. Samples were placed in the wells and incubated with 500 μL of a solution of basic fibroblast growth factor (bFGF, R&D Systems, Minneapolis, Minn., 10 ng/mL in PBS) for 2 h. After seven washes with 0.05 wt % Tween20 in PBS (PBS-T), 500 μL of a solution of bFGF antibody was added (R&D Systems, Minneapolis, Minn., 2 μg/mL in PBS) and incubated for 2 h. The samples were washed seven more times with PBS-T. The samples were then incubated for 30 min in a 500 μL solution consisting of 1 μL horseradish peroxidase conjugated NeutrAvidin (Pierce, Rockford, Ill., 1 mg/mL), 8 mL PBS, and 2 mL SuperBlock™ Blocking Buffer (Pierce, Rockford, Ill.). The fibers were then washed seven times with PBS-T and incubated in 500 μL of TMB substrate solution (Pierce, Rockford, Ill.) for 10-12 mins. Absorbance at 450 nm was measured. All absorbance values were normalized with respect to a well treated with bFGF and antibody, as explained previously, but without any electrospun fibers. The growth factor binding assay was completed three times and the average values are reported.

Results

Electrospinning Physical Mixtures (1:4) of LMWH and PEO

A 1.4 LMWH to PEO mixture (25 mg LMWH and 100 mg PEO) was dissolved in water and electrospun. The fibers resembled typical electrospun PEO fibers with an approximate diameter of 100-400 nm and were slightly beaded. The presence of microspheres with an average diameter of 1-5 μm was also observed. Two control solutions were made. One control consisted of a 10 wt % PEO/H2O and the other a 10 wt % LMWH/H2O. The 10 wt % PEO/H2O solution electrospun
to form PEO fibers with a diameter of 100-400 nm. The fibers were circular in their shape and contained beads (200-600 nm in diameter) but no microspheres were observed. The 10 wt % LMWH/H2O control did not form fibers or microspheres, which is almost certainly due to the lack of entanglements in the negatively charged LMWH (3,000 g/mol). Attempts to electrospin higher MW heparin (12,000 g/mol) also failed for similar reasons.

Toluidine blue assays were performed on the electrospun physical mixtures of PEO and LMWH to determine if LMWH was present in the sample. It was found that 86 ± 7.15 of LMWH was present per mg of electrospun fibers. The presence of LMWH indicated by the toluidine blue assay is consistent with the presence of LMWH in the matrix.

EDX was employed to determine the location of the heparin in the fiber matrix via detection of sulfur on the sulfated heparin; the results of the EDX analysis are outlined in Table 1. The presence of aluminum in the sample is due to the aluminum SEM mount used to hold the fibers. PEO fibers served as a control for this experiment; EDX detected 46% C, 5% O, and 49% Al in the PEO fibers, consistent with the composition of PEO. The significant amount of C detected was most likely due to carbon adhesive tab that was used to secure the fibers for imaging. A thin film was cast of 10 wt % LMWH/H2O and used as the second control. The atomic composition detected via EDX was 23% C, 40% O, 17% S, and 18% Na, consistent with the presence of LMWH in the sample (sodium is the counterion for the LMWH used in these studies). The 1:4 LMWH:PEO electrospun sample was tested in three different areas: the fiber portion, bead portion, and the microsphere. The fibers contained 42% C, 5% O, and 59% Al. Since no sulfur or sodium was detected, the results suggest that either the fiber section of the matrix consists of primarily PEO or that the concentration of sulfur is too low for detection via EDX. Generally, the lower limit of detection for EDX is approximately 1%, so it is possible that the LMWH may be incorporated into the fibers but at a concentration much lower than 1%. The beaded section of the matrix was found to contain 61% C, 13% O, 26% Al, and 0.3% S. The detection of the sulfur indicates that LMWH is present, at low concentrations, in the beaded areas of the electrospun mat. The microspheres were shown to contain 73% C, 20% O, 4% Al, 1.2% S, and 1.4% Na. The presence of sulfur and sodium imply that LMWH is present in the microspheres at higher concentrations than found in the beaded sections of the mat. The EDX results are consistent with the expected composition of the fibers, and the varying amount of sulfur in the different regions suggests that LMWH is not uniformly incorporated into the fibers via simple mixing.

**TABLE 1**

<table>
<thead>
<tr>
<th>Sample</th>
<th>C (%)</th>
<th>O (%)</th>
<th>Al (%)</th>
<th>S (%)</th>
<th>Na (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEO Fibers</td>
<td>46 ± 14.7</td>
<td>5.0 ± 1.15</td>
<td>49 ± 14.2</td>
<td>ND*</td>
<td>ND</td>
</tr>
<tr>
<td>LMWH Film</td>
<td>23 ± 1.63</td>
<td>40 ± 2.16</td>
<td>ND</td>
<td>17 ± 1.41</td>
<td>18 ± 2.50</td>
</tr>
<tr>
<td>1:4 LMWH:PEO</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fiber section:</td>
<td>42 ± 9.02</td>
<td>5.0 ± 0.577</td>
<td>59 ± 18.9</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>bead section:</td>
<td>61 ± 2.65</td>
<td>13 ± 2.31</td>
<td>26 ± 4.51</td>
<td>0.3 ± 0.025</td>
<td>ND</td>
</tr>
<tr>
<td>microsphere:</td>
<td>73 ± 2.52</td>
<td>20 ± 5.13</td>
<td>4.0 ± 1.66</td>
<td>1.2 ± 0.48</td>
<td>1.4 ± 0.13</td>
</tr>
</tbody>
</table>

*ND = not detected

**Electrospinning Dye-Labeled LMWH with PEO**

To visually map the location of the LMWH throughout the electrospun mat, a fluorescent dye, Alexa Fluor 350®, was covalently attached to LMWH, and the fibers were analyzed via LSCM; observation of fluorescence permits direct observation of the presence and location of LMWH throughout the electrospun matrix. PEO (10 wt %) was mixed with Alexa Fluor 350-labeled LMWH (0.2 wt %) and electrospun. FIG. 1 shows resulting fibers with diameters of approximately 100-200 nm, with a few very large beads approximately 6 µm in diameter.

The fibers were then analyzed via LSCM to determine if the LMWH-dye molecules were incorporated into the matrix and to determine their distribution in the matrix. Electrospun PEO fibers were used as a control; results for the control are shown in FIG. 2. FIG. 2a shows data in reflection mode and confirms that fibers were present on the glass coverslip. FIG. 2b shows two small areas of fluorescence that are likely impurities in the PEO or dust in the sample, but confirms the complete lack of background fluorescence in the PEO fibers. FIG. 3 presents LSCM data for electrospun fibers of the LMWH-dye/PEO mixture. The results demonstrate the fluorescence of the fibers, indicating the presence of LMWH. In contrast to SEM and EDX results, the LSCM results also suggest that the LMWH-dye is present not only in the beaded sections of the matrix, but also in the fiber regions. FIG. 3 shows the fluorescence of the fibers due to LMWH-dye incorporation. Z-stack images were also taken (not shown) to ensure that the LMWH-dye is present throughout the entire depth of the matrix and is not localized in any one area. Due to the LSCM limit of resolution, approximately 200 nm, the exact location of the heparin within each individual fiber is unknown. However, all LSCM images indicate that LMWH is present throughout the depths of the electrospun matrix, suggesting a fairly uniform dispersion of LMWH. Measurement of LMWH via toluidine blue assay confirmed the presence of approximately 4.3 µg (+/-0.923) of LMWH per mg of electrospun sample. A direct comparison cannot be made between the amount of LMWH in this sample and the amount in the physical mixtures of LMWH and PEO due to differing amounts of LMWH in the initial solutions. Nevertheless, these results suggest the opportunities for facile incorporation of bioactive polysaccharides into electrospun matrices.

**Incorporation of PEG-LMWH-Dye in PEO for Electrospinning**

LMWH was covalently attached to the termini of a 4-arm star PEG and evaluated for its incorporation into an electrospun matrix. PEG-LMWH-dye (0.2 wt %) was mixed with PEO (10 wt %) in water. The electrospun fibers from this solution were analyzed via FESEM, with results shown in...
FIG. 6. As is shown in FIG. 6, the resulting fibers were 100-300 nm in diameter with the presence of microspheres (1-3 μm). The morphology of the PEG-LMWH fibers was very similar to those produced from the earlier samples with free LMWH. In both electrospun mats, fibers are in the nanometer size range and the onset of bead formation is observed by the roughness of the fibers (see FIGS. 1 and 4).

The fiber matrix was then analyzed via LSCM to confirm that the PEG-LMWH-dye molecule was incorporated in the electrospun fibers; representative results are shown in FIG. 5. Similar to the results in FIG. 3, the data shown here also indicate that the fibers are evenly fluorescent across the matrix, showing that the PEG-LMWH was evenly distributed in the PEO fiber matrix. These fibers were found to contain 3.5 μg (+/-0.397) of heparin per mg of electrospun fibers. These results indicate a slight improvement in LMWH incorporation in comparison to the LMWH/PEO fibers, and may suggest that PEG-LMWH permits the incorporation of slightly more heparin than in the fibers produced using free heparin.

Changing the Matrix Polymer

Multiple polymers could be used as the matrix polymer. PLGA was chosen as an alternate carrier polymer for the LMWH systems due to the success of PLGA in biomaterial applications. PLGA/DMF (45 wt %) was electrospun with LMWH-dye (0.2 wt %) and also with PEG-LMWH-dye (0.2 wt %). Due to differences in molecular weight and viscosity, the concentration of carrier polymer is different than those used for PEO electrospinning, but all other processing conditions remained the same. The electrospun PLGA fibers are approximately 400-800 nm in diameter, (FIG. 6a). SEM revealed that fiber morphology was not affected by the incorporation of LMWH-dye or PEG-LMWH-dye, (FIGS. 6b and 6c).

LSCM showed that the PLGA electrospun mat, shown in FIG. 7a under transmitted light, does not fluoresce to any significant extent. As encountered previously with PEO fibers, there is a small area of fluorescence in FIG 7a, which is likely due to polymer impurities or dust on the sample. The images shown in FIG. 8 reveal that both LMWH-dye and PEG-LMWH-dye were incorporated into the PLGA matrix and z-stack LSCM images confirm that the heparin is present throughout the depths of the matrices. The toluidine blue assay indicated that there is approximately 8.41 μg (+/-0.532) of LMWH present per mg of electrospun LMWH/PLGA sample. The PEG-LMWH/PLGA sample contained 9.50 μg (+/-0.382) of LMWH per mg of electrospun fibers. The results of the FESEM, LSCM, and the toluidine blue assays suggest that the carrier polymer can be changed without affecting the incorporation of heparin or fiber morphology.

Example 2

Growth Factor Release Assays of Electrospun Fibers

An ELISA format was employed to characterize the binding of bFGF in a series of samples: a blank well, PLGA fibers alone, LMWH/PLGA fibers, and PEG-LMWH/PLGA fibers. Growth factor release studies were performed using a Quantikine Human FGF Basic Kit (R&D Systems, Minneapolis, Minn.). Incubation of the growth factor was completed using a QuantiChem Immunometric assay following the protocols of the manufacturer (R&D Systems, Minneapolis, Minn.). The optical density measurements, at a wavelength of 450 nm, resulted in the following absorbance values relative to the control (increasing absorbance values correlate with increasing growth factor binding): PLGA fibers 1.59 (+/-0.055), LMWH/PLGA fibers 2.46 (+/-0.146), and PEG-LMWH/PLGA fibers 3.59 (+/-0.106). FIG. 9 shows that there are significant differences in bFGF binding between the LMWH/PLGA and PEG-LMWH/PLGA fibers, despite the fact that the toluidine blue assays show that the two matrices contain similar amounts of LMWH after electrospinning. Since both the LMWH and PEG-LMWH samples began with similar amounts of heparin but did not exhibit the same level of bFGF binding, these data suggest that the PEG-LMWH may be retained in the electrospun fibers more effectively than LMWH alone. FESEM characterization of the electrospun membranes after the growth factor binding assay revealed that the PLGA fibers exhibited no visible signs of degradation during the time frame of the growth factor binding study (FIG. 10, parts a and b). This observation corroborates the fact that differences in growth factor binding likely result from differential LMWH retention rather than from variations in fiber degradation between samples. These electrospun membranes were also incubated in PBS for an additional 1 day, 3 days, and 14 days to determine if any fiber degradation occurred (FIG. 10, parts c-h). These SEM images show that there are no visible signs of fiber degradation for the time period studied in this investigation.

Characterization of the fibers after completion of the growth factor binding assay was conducted via multiphoton microscopy. FIG. 11, parts a and b, shows the LMWH retention within the electrospun fibers after the growth factor assay, or 6 h of PBS incubation. After only 6 h in PBS, slight differences in the amount of LMWH within the fibers were observed via multiphoton microscopy; these differences were much more pronounced with an additional 24 h incubation in PBS (FIG. 11, parts c and d). In FIG. 11, parts e-h, the multiphoton images are shown in fluorescence and reflection mode. This was necessary due to the small amount of fluorescence in the samples in order to prove that fibers are present. In FIG. 11, parts g and h, the most visible differences are observed. After 14 days incubation in PBS, the PEG-LMWH-dye fibers still exhibit a moderate level of fluorescence in comparison to the LMWH-dye fibers, which show minimal signs of fluorescence. The differences in the amount of LMWH retained in the fibers were also observed throughout the depth of the matrix, as confirmed via z-stack images (see FIG. 12 for a representative z-stack image of PEG-LMWH-dye fibers after 14 days incubation in PBS).
rates were due to the short incubation time of 24 h. However, the 21 day release consistently showed less than 1% bFGF release for all samples. Similar results were obtained in release studies conducted at 37°C. In order to determine if any bFGF remained in the electroporated matrices after these release studies, a binding study was completed on the 0.2 wt% heparin-containing fibers after 5 h and 24 h release in PBS. FIG. 14 is a digital picture showing the visual differences in the binding of bFGF to the fibers. The more intense the blue color, the more bFGF present. This picture clearly shows dramatic differences in binding to the PEG-LMWH fibers versus LMWH and PLGA only fibers. However, more LMWH is present in the PEG-LMWH dye fibers. This suggests that either 1) more bFGF is retained in the PEG-LMWH dye fibers due to the reduced diffusion times of the PEG-LMWH-dye complex or 2) all fibers may contain similar amounts of residual bFGF but the PEG-LMWH-dye fibers protect the structure of the bFGF and, thus, apparently more growth factor is detected by the immunochemical assay.

**Example 3**

**Cell Proliferation Assay**

The PEG-LMWH/PLGA, LMWH/PLGA, and PLGA fiber matrices were tested to determine if there were any differences in the ability of the membranes to affect cellular proliferation of MG63 (human osteosarcoma) cells. PLGA, LMWH/PLGA, and PEG-LMWH/PLGA electrospun membranes were sterilized under UV light for 4 h and incubated in 1.5 ml Dulbecco’s Modified Eagle Medium (DMEM) containing 5% (v/v) fetal calf serum (FCS), bFGF (10 ng/ml), penicillin (100 U/ml) and streptomycin sulfate (100 µg/ml) for 2 h. The membranes were then washed 2-3 times with sterile PBS. All membranes were incubated in bFGF (15 ng/membrane) prior to the cell proliferation assay. The membranes were then placed in 24-well tissue culture dishes containing a MG63 cell (2x105 cells/ml, American Type Culture Collection, Manassas, Va.) suspension in DMEM supplemented with 5% (v/v) FCS. The plates were shaken every 30 min for 4 h. The scaffolds were then transferred to a new 24-well plate and incubated in DMEM containing 1% (v/v) FCS at 37°C in an atmosphere of 95% air and 5% CO2. Culture medium containing 1% (v/v) FCS was changed every 3 days. Cultures were terminated on days 1, 3, 6, 9, 12, and 15. MG63 proliferation was determined by immunodetection of bromodeoxyuridine (Brdu) incorporation (Cell Proliferation ELISA Biotak System, Amersham Biosciences, Piscataway, N.J.), according to the manufacturer’s instructions. Cells seeded on the electroporated membranes were labeled with Brdu and then incubated with peroxidase-labeled anti-BrdU antibody. Excess anti-BrdU antibody was removed by washing the membranes with washing buffer in a vortex mixer. The membranes were then incubated in TMB substrate to produce a blue color, the more bFGF present. This picture clearly shows dramatic differences in cellular proliferation due to the presence of PEG-LMWH. Based on the results of this cellular assay it is believed that PEG-LMWH increases the rate of cell proliferation in comparison to the other samples due to the retention of PEG-LMWH in the matrix that causes increased retention and slower release of bFGF, which has been suggested in previous results presented in FIG. 14. The increased retention of bFGF may support higher cell proliferation rates. Although this was a very preliminary cell study, it does indicate that there are functional differences between electroporated matrices functionalized with either PEG-LMWH or LMWH alone.

**Example 4**

**Functionalized Cross-Linked Matrices**

**Materials**

All materials were obtained and purified as described in Example 1.

**Methods**

**Synthesis of PEG-LMWH Conjugates**

The synthesis of the PEG-LMWH conjugate exploited in hydrogel assembly was conducted via Michael-type addition reactions between maleimide functionalized heparin and thiol-terminated four-arm star PEG, as described in Example 1. The degree of LMWH functionalization in PEG-LMWH was determined to be 81% via 1H NMR spectroscopy. Synthesis of PEG-LMWH-Alexa Fluor 350 was conducted via similar protocols as previously described in the art.

**Synthesis of PEG-HBP Conjugates**

All HBPs were prepared on Rink Amide MBHA resin via solid phase peptide synthesis with Fmoc-protection using a PTI PS 3 peptide synthesizer (Protein Technologies Inc, Tucson, Ariz.) and purified via preparative-scale reverse-phase HPLC. The PF4-ZIP sequence CCGGRMKOLED-KVKKLLKYNHLEVARLKKVLG was based on a GCN4 coiled coil and mimics the heparin-binding domain of human platelet factor 4. The heparin-binding peptides, ATIII and HBP, from antithrombin III (ATIII) and heparin interacting protein (HIP), have sequences of CBkAKLARLYRKA and CRPKKAKAKAKDQTK, respectively. Any heparin-binding peptide of sufficient affinity and appropriately slow dissociation (from heparin) would be equally applicable for use in these hydrogels. Peptides isolated as single fractions via HPLC were characterized via MALDI and ESI mass spectrometry. The mass of the purified HBPs was confirmed via ESI mass spectrometry. For example, for PF4-ZIP, m/z=992.5 [M+4H]+, calc’d 992.0] and m/z=1322.9 [M+3H]+, calc’d 1322.7. Similar agreement between theoretical and observed mass values was observed for all other HBPs.

The synthesis of the PEG-HBP conjugates utilized in hydrogel assembly was conducted via Michael addition reactions between vinyl sulfone-terminated four-arm PEG and eucine-terminated PF4 ZIP peptide.

**Characterization**

Peptides, PEG-LMWH, and PEG-HBPs were characterized via 1H NMR spectroscopy and MALDI-TOF Mass Spectrometry to determine purity, composition, and degree of functionalization.
Circular Dichroic Spectroscopy (CD)

CD spectra were measured at 5° C to 75° C on a JASCO J-810 spectropolarimeter (Jasco Inc., Easton, Md.) equipped with a Jasco PTC-424S temperature controller. Samples were equilibrated at the desired temperature for 30 minutes prior to data collection. Equilibration was indicated by the absence of further changes in the CD signal at longer equilibration times. All CD spectra were taken in a 1 mm path length quartz cuvette, at wavelengths from 200 to 250 nm. Data points were recorded at every nanometer with a 4.0 response time. The concentrations of peptide samples were determined via amino acid analysis for calculation of mean residue ellipticities.

Heparin Affinity Measurements

Heparin-Sepharose affinity liquid chromatography was performed on an AKTA Explorer FPLC equipped with a HiTrap Heparin HP column (5 ml, 10 mg heparin/ml gel, Amersham Biosciences Corp., Piscataway, N.J.). Surface Plasmon Resonance (SPR). SPR sensorgrams were recorded on a BIAcore 3000 instrument (Bioscience Inc, Piscataway, N.J.), employing a high-capacity LMWH surface created on a commercially available streptavidin-coated chip via treatment with biotinylated LMWH.

Bulk Rheology Experiments

Bulk rheology experiments of the PEG-LMWH/PEG-HBP hydrogels were conducted at 25 or 37° C on a stress-controlled rheometer (MCR 500, Paar Physica, Anton-Paar, Ashland, Va.) with a 25.0 mm diameter parallel plate geometry and a 1 mm gap distance. Strain sweeps were performed on samples from 0.001% to a maximum strain of 100% to determine the limit of the linear viscoelastic regime (LVE). At a constant strain of 0.1%, chosen from the LVE, frequency sweeps ranging from 0.1 Hz to 100 Hz were conducted. Shear recovery experiments were also performed for the PEG-PF~4~ ZIP-containing hydrogels, and prior to these experiments, a baseline oscillation at a constant strain of 0.1% and a constant frequency of 10 Hz was performed, followed by a high-speed rotation with a 1000 s-1 shear rate for 10 s. The recovery was then measured with a time sweep experiment at a constant strain of 0.1% and a constant frequency of 10 Hz.

Fluorimetry Experiments

Fluorimetry experiments to measure the concentration of PEG-LMWH-Alexa Fluor 350 (in eroded solutions of PEG-PF~4~ ZIP-containing hydrogels) were performed using a FluoroMax-3 spectrofluorometer (Jobin Yvon Inc, Edison, N.J.) with a xenon arc lamp illuminator. Erosion of PEG-LMWH from other PEG-HBP-containing hydrogels was determined gravimetrically. 45 µL of each sample were loaded into a cuvette and excited at 346 nm, the excitation spectra peak value of Alexa Fluor 350. The emission spectrum peak value at 442 nm was recorded. Solutions of PEG-LMWH-Alexa Fluor 350 in PBS, with concentrations from 5.42x10^-4 wt % to 4.23x10^-6 wt %, were employed for generation of the standard curve. For erosion profile experiments, the PEG-LMWH-Alexa Fluor 350 was premixed with the PEG-LMWH at a weight ratio of 1:158. The fluorescence intensities of the PEG-LMWH-Alexa Fluor 350 in the eroded PEG-LMWH were then measured and permitted calculation of the percentage of PEG-LMWH eroded from the hydrogels in hydrogel erosion experiments.

Assembly of PEG-LMWH/PEG-HBP (and PEG-LMWH/GF) Hydrogels

The PEG-LMWH/PEG-HBP hydrogels were formed by the interaction between LMWH and PF~4~ ZIP. 5 wt % solutions of the PEG-HBP in PBS were added directly to 2.5 wt % solutions of the PEG-LMWH in PBS, to afford hydrogel networks at a final composition of 2.5 wt % total polymer. The solutions were mixed in ligand mole ratios of 9:0.5, 8:1, and 7.5:2.5 (LMWH:PF~4~ ZIP dimer); other ligand mole ratios are also useful for hydrogel assembly. For VEGF-crosslinked hydrogels, an 8 wt % solution of PEG-LMWH in PBS is mixed with varying amounts of solid VEGF (0.1-20 µg) to afford a self-supporting gel upon sufficient addition of VEGF. After mixing, the hydrogels were stored at 4° C. The stored hydrogels were equilibrated to room temperature prior to rheological characterization (typically several minutes).

bFGF Release and Hydrogel Erosion Experiments

bFGF release and hydrogel erosion experiments were performed at 4° C in 24-well polystyrene assay plates (Corning Inc., Corning, N.Y.), blocked with PBS containing 5% BSA and 0.05% Tween 20 (Sigma, St. Louis, Mo.). The wells were aspirated and washed 4 times with 0.05% Tween 20 in PBS before loading samples. Afterward, 200 µL hydrogel was placed on the bottom of each well and 2.8 mL PBS was added carefully over each gel. 1 mL PBS was taken out of the well at 1, 2, 6 and 24 h and then each following day, followed by replacement with 1 mL fresh PBS. The amount of bFGF in each sample was measured with a bFGF Quantikine Kit (R&D Systems, Minneapolis, Minn.). The hydrogel erosion kinetics were conducted on the same samples used for bFGF release experiments.

Results

Oligomerization of PF~4~ ZIP

Our initial studies were aimed at determining the oligomerization properties of the coiled-coil PF~4~ ZIP, as such information is relevant to the subsequent use of the PF~4~ ZIP in hydrogel formation. No such characterization was necessary for the other HBPs, as they do not form higher-order assemblies. Circular dichroic spectroscopy studies were conducted to assess the folding of the PF~4~ ZIP under various conditions. Solutions of PF~4~ ZIP dissolved in PBS were scanned from 250 nm to 200 nm at varying temperatures between 5° C and 75° C. The CD spectra of PF~4~ ZIP at a variety of temperatures show an isodichroic point at 203 nm, validating the existence of a two-state equilibrium. At temperatures below 55° C, the spectra observed exhibit two minima at 208 nm and 222 nm, demonstrating that PF~4~ ZIP exists in the coiled-coil state under conditions of interest for hydrogel applications. As seen by the appearance of a single minimum at 203 nm in the data collected at elevated temperatures, the structure of PF~4~ ZIP reversibly changes to random coil at elevated temperature. Maximum mean residue ellipticity values at 222 nm (MRE222) were measured to be ~30,470 deg cm^2 dmol^-1 for the PF~4~ ZIP at 15° C, consistent with reported values ranging from ~25,000 to ~35,000 deg cm^2 dmol^-1 for various G(4)CNa~4~ mimic peptides in PBS at 15° C.

The conformation of PF~4~ ZIP at various concentrations was also monitored via CD. At all measured concentrations, the spectra observed exhibit two minima at 208 nm and 222 nm, demonstrating the helical character of PF~4~ ZIP under these conditions. The measured MRE222 for a solution of 56 µM PF~4~ ZIP in PBS is ~24,580 deg cm^2 dmol^-1, which is consistent with the value reported for 40-60 µM PF~4~ ZIP in 3 mM sodium citrate buffer (~27,000 deg cm^2 dmol^-1). The difference between the measured ellipticity and the ellipticity of the unfolded monomer is related to concentration and can be fit to determine the Kd of the dimerization, via standard fitting procedures well-described in the literature. The calculated equilibrium constant of unfolding, Kd, is 3.48±0.03 µM. Solutions of PF~4~ ZIP attached to star-Peg were also studied via CD, to ensure that conjugation to Peg did not significantly alter the association of the PF~4~ ZIP coiled-coils. As shown in FIG. 17(a), the spectra of Peg-PF~4~ ZIP are essentially identical to the spectra obtained for the isolated PF~4~ ZIP.
Slight differences in MRE values likely arise from uncertainties in the precise peptide concentrations for the PEG-PF\textsubscript{4}ZIP samples. The K\textsubscript{D} value derived from the best fit of the concentration dependence of (FIG. 17(b)) for PEG-PF\textsubscript{4}ZIP is 0.93\,µM. The PF\textsubscript{4}ZIP concentrations during NMR characterization and hydrogel formation and characterization are always much greater than these measured K\textsubscript{D} values (e.g., 200 µM and higher), suggesting that PF\textsubscript{4}ZIP will exist as a fully folded dimer under those conditions.

**Heparin-Binding Affinity**

Our previous investigations of PEG-LMWH/PEG-HBP hydrogels suggested that the viscoelastic properties of the noncovalently assembled hydrogels were related to the heparin-binding kinetics and affinities of the peptides (from antithrombin III (ATIII) or heparin interacting protein (HIP)). Heparin-agarose affinity chromatography and SPR experiments were therefore used to compare the heparin-binding affinity of the various HBPs. Results of these experiments are summarized in Table 2.

### Table 2

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Salt required for elution from heparin column (mM)</th>
<th>k\textsubscript{a} (M\textsuperscript{-1}s\textsuperscript{-1})</th>
<th>k\textsubscript{d} (s\textsuperscript{-1})</th>
<th>K\textsubscript{D} (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATIII\textsuperscript{a}</td>
<td>594 ± 2</td>
<td>1.56 ± 0.06 x 10\textsuperscript{7}</td>
<td>2.00 ± 0.3 x 10\textsuperscript{2}</td>
<td>12.9 ± 1.3</td>
</tr>
<tr>
<td>HIP\textsuperscript{a}</td>
<td>687 ± 1</td>
<td>1.10 ± 0.08 x 10\textsuperscript{8}</td>
<td>4.64 ± 0.02 x 10\textsuperscript{5}</td>
<td>4.20 ± 0.3</td>
</tr>
<tr>
<td>PF\textsubscript{4}ZIP</td>
<td>962 ± 10</td>
<td>2.24 ± 0.05 x 10\textsuperscript{8}</td>
<td>2.56 ± 0.10 x 10\textsuperscript{5}</td>
<td>1.15 ± 0.03 x 10\textsuperscript{-2}</td>
</tr>
</tbody>
</table>


For heparin affinity chromatography experiments, HBPs were loaded onto a heparin-Sepharose column, and then eluted with buffer of increasing NaCl concentration. The concentration of NaCl required for peptide elution is used as an indication of the affinity of the peptide for heparin. The elution of the peptide from the heparin-Sepharose column required a salt concentration of 962±10 mM for the PF\textsubscript{4}ZIP peptide. The salt concentration required to elute PF\textsubscript{4}ZIP (962±10 mM) is higher than that measured for the ATIII peptide (594±2 mM) and for the HIP peptide (687±1 mM), indicating that PF\textsubscript{4}ZIP has higher heparin-binding affinity than the ATIII and HIP peptides and should therefore be competent for hydrogel assembly. These results are consistent with previous reports indicating that similarly high concentrations of NaCl were required to elute \textsuperscript{125}I-labelled PF\textsubscript{4}ZIP bound to a heparin-Sepharose column in 0.02 M Tris-Cl buffer pH 7.0 containing 0.05 M NaCl.

In SPR experiments, the interaction of the peptides with a LMWH-modified SA chip surface was determined under conditions described in the experimental section. Neither nonspecific binding of heparin-binding proteins to SA chips nor chip instability was observed in any of the SPR measurements. In addition, no mass transport limitation or linked reactions were indicated. The measured association of the PF\textsubscript{4}ZIP with LMWH proceeds with a rate constant of 2.24±0.05 x 10\textsuperscript{17} M\textsuperscript{-1}s\textsuperscript{-1}, while the dissociation proceeds with a rate constant of 2.56±0.10 x 10\textsuperscript{-3} s\textsuperscript{-1}, yielding a KD of approximately 1.15±0.03 x 10\textsuperscript{-2} µM. These faster association kinetics, relative to those reported for the ATIII and HIP (Table 2) (see also N. Yamaguchi, B. S. Chae, L. Zhang, K. L. Kiick, E. M. Furst, *Rheological characterization of polysaccharide-poly(ethylene glycol) star copolymer hydrogels*, Biomacromolecules 6 (4) (2005) 1931-1940).

The measured and off rates fluctuate only slightly throughout the temperature range, suggesting that noncovalently assembled hydrogels based on PF\textsubscript{4}ZIP and LMWH interactions should exhibit consistent mechanical properties at these temperatures.

PEG-LMWH/PEG-HBP Hydrogel Formation

Via \textsuperscript{1}H NMR spectroscopy, functionalization of the star PEG with HBPs was determined to be at least 59%, indicating that PEG-HBPs meet the functional requirement (at least one binding partner exhibits >2) for crosslinking a hydrogel upon interaction with PEG-LMWH (which showed a functionalization of 81%, as determined via NMR). (See N. Yamaguchi, K. L. Kiick, *Poly saccharide-poly(ethylene glycol) star copolymers as scaffolds for the production of bioactive hydrogels*, Biomacromolecules 6 (4) (2005) 1921-1930; and N. Yamaguchi, B. S. Chae, L. Zhang, K. L. Kiick, E. M. Furst, *Rheological characterization of polysaccharide-poly(ethylene glycol) star copolymer hydrogels*, Biomacromolecules 6 (4) (2005) 1931-1940).

Accordingly, solutions of the two polymer conjugates in PBS (2.5 wt% of PEG-LMWH and 5 wt% of PEG-HBP) were mixed at various ligand mole ratios to form hydrogels. Ligand mole ratios of 9:0.5 and 7.5:2.5 (LMWH:PF\textsubscript{4}ZIP) were used to yield the PEG-LMWH/PEG-PF\textsubscript{4}ZIP hydrogels. Similar ratios were used for the formation of functionalized crosslinked matrices from mixtures of PEG-LMWH with either PEG-ATIII or PEG-HIP, and any PEG-HBP conjugate should be useful in a similar manner. The application of such ratios was employed to maximize the
excess LMWH available for growth factor binding (see below). Before addition of PEG-PF 4 ZIP, the 2.5 wt % of the PEG-LMWH was uniform and transluent. In addition, the water-like viscosity of the PEG-PF 4 ZIP solution indicated that there was no significant crosslinking of the peptide-terminated star polymers via intermolecular coiled-coil formation, although some oligomers of the PEG-PF 4 ZIP bioconjugates may exist in solution. The formation of self-supporting, opaque gels was immediately apparent upon mixing the two polymer solutions. A schematic of the assembly of the hydrogels is shown in FIG. 18. This assembly is operative regardless of the identity of the PEG-HBP.

**Bulk Rheology**

The mechanical properties of the PEG-HBP containing hydrogels were characterized via rheological frequency sweep experiments on bulk samples. The frequency sweep results for PEG-LMWH/PEG-PF 4 ZIP hydrogels (FIG. 19) show that the storage modulus G'(w) is significantly larger than the loss modulus G''(w) over all measured frequencies and G''(w) exhibits a pronounced plateau extending to frequencies of tens of reciprocal seconds, indicating a viscoelastic gel. Essentially identical results are obtained regardless of the identity of the PEG-HBP. The magnitude of G'(w) and G''(w) also increases as the molar ratio of the peptide component is raised. The average G'(w) increases from an average value of 70 Pa for PEG-LMWH to approximately 80 and 180 Pa for hydrogels with molar ratios of LMWH to PF4ZIP of 9:0.5 and 7.5:2.5, respectively. The average G''(w) also increases monotonically with higher molar ratio of the peptide component, from less than 10 Pa for PEG-LMWH to more than 30 Pa for hydrogels with molar ratios of LMWH to PF4ZIP of 7.5:2.5. Bulk rheology experiments were also performed on the samples at various gap heights of 1 mm, 5 mm, and 0.25 mm. At frequencies from 0.1 to 63 Hz, the observed identical dynamic moduli at different gap heights indicate that no significant slipping occurs in that frequency range.

The strengthening effects on storage modulus upon addition of PEG-HBP to PEG-LMWH are presented in FIG. 20 for G'(w=0.1 Hz) plotted as a function of the ratio of HBP to LMWH in the samples, with moduli normalized by the initial storage modulus of PEG-LMWH. The plateau in the modulus with increasing PF 4 ZIP or HIP concentration may imply that the HBP-binding sites on LMWH have been saturated. The increase in the elastic modulus upon addition of PEG-PF 4 ZIP for the PEG-LMWH/PEG-PF 4 ZIP hydrogels is lower than that observed with addition of PEG-HBP for the PEG-LMWH/PEG-ATIII or the PEG-LMWH/PEG-HIP hydrogels. Literature reports suggest that at least 4 tetrasaccharides (16 units) are required for efficient heparin-PF 4 protein interactions, while HIP- and ATIII-binding sites are believed to be similar pentasaccharides in heparin. The fewer PF 4-binding sites on LMWH could lead to the lower storage modulus plateau value and lower slope in FIG. 20 for the PEG-LMWH/PEG-PF 4 ZIP hydrogels than that observed for the PEG-LMWH/PEG-ATIII or the PEG-LMWH/PEG-HIP hydrogels. These results indicate two things. First, the mechanical properties of the hydrogels are initially established by the self-interaction/assembly of PEG-LMWH. Second, the dependence of storage modulus on HBP:LMWH ratio clearly indicates that the PEG-HBPs mediate crosslinking of the networks and that the interactions between HBP and LMWH modulate the mechanical properties of the matrices.

A similar dependence of rheological properties on the concentration of heparin-binding cross-linker was observed for PEG-LMWH crosslinked with VEGF.

**Growth Factor Release and Hydrogel Erosion**

The release of growth factors from these hydrogels in vitro has also been investigated. Although covalently crosslinked, heparin-containing hydrogels have been shown to be useful for release of bFGF, physically crosslinked hydrogels could provide an alternative protein-delivery matrix without the need for potentially toxic crosslinking reagents.

The bFGF release and hydrogel erosion experiments were performed at 4°C in 24-well polystyrene assay plates. A 2.5 wt % solution of PEG-LMWH with bFGF was prepared via dissolving PEG-LMWH and bFGF in PBS at a final molar ratio of approximately 1:1,500,000 (bFGF to LMWH). Second, a 5 wt % solution of PEG-PF 4 ZIP (or other PEG-HBP) in PBS was added to the PEG-LMWH/bFGF at a ligand molar ratio of 8:1 (LMWH:PF4ZIP dimer). Other molar ratios can also be used, depending upon the desired rate of release of the growth factor and/or desired rate of erosion of the network. Assuming that all HBPs on the PEG-HBP termini bind LMWH, the molar ratio of bFGF to available LMWH in the PEG-LMWH/PEG-HBP hydrogels is approximately 1:1,300,000.

Data from studies of bFGF release from PEG-LMWH/PEG-HIP and PEG-LMWH/PEG-PF 4 ZIP hydrogels are summarized in FIG. 23. As shown in the figure, a burst release of bFGF ranging from 10 to 25% (depending on gel identity) is observed, followed by a slow release of bFGF over 10 days, to a maximum measured release ranging from approximately 20 to 35%. Such release profiles are of potential use in neovascularization, wound repair, and tissue engineering.
applications. As shown in FIG. 23, the bFGF is released slightly more quickly from the PEG-LMW/PEG-PF/ZIP hydrogels than from the PEG-LMW/PEG-HIP hydrogels, indicating that the rates of release of growth factor from these hydrogels are tunable based on hydrogel composition. The PEG-LMW/PEG-HIP hydrogel demonstrates higher storage and loss moduli than the PEG-LMW/PEG-PF/ZIP hydrogels. The observed burst release is similar in value to previously reported burst release in other heparinized hydrogel systems, and the linear release following the initial burst in those hydrogel systems has been successfully applied to stimulate cell proliferation.

Hydrogel erosion kinetics are also shown in FIG. 23. In the case of the PEG-LMW/PEG-PF/ZIP hydrogels, PEG-LMW-Alexa Fluor 350 was pre-mixed with PEG-LMW at a weight ratio of 1:158 to facilitate tracking of the eroded PEG-LMW via fluorimetry. The erosion profile of the PEG-LMW/PEG-HIP hydrogels was determined gravimetrically in the transwell assay format in conjunction with the bFGF release experiments. As shown in the figure, a burst erosion of 10 to 30% is initially observed (depending on hydrogel composition), followed by a slow erosion to a maximum of 30 to 50% (again, depending on hydrogel composition). As is also indicated in this figure, the growth factor release is directly correlated to the erosion of the hydrogel, and can therefore be controlled by modulating hydrogel mechanical properties. Modulating the affinity of the growth factor to the hydrogel will also serve as an additional strategy to control release rates.

Growth factors released from hydrogels of these general compositions have also been shown to be bioactive, indicating the utility of these matrices in desired applications. For example, bFGF released from PEG-LMW functionalized hydrogels (covalently crosslinked model systems) (procedure for covalent crosslinking is provided in N. Yamaguchi, K. L. Kiick, Polysaccharide-poly(ethylene glycol) star copolymers as scaffolds for the production of bioactive hydrogels, Biomacromolecules 6 (4) (2005) 1921-1930, which is incorporated herein by reference) has been shown, via MTX (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyldltrazolium bromide) proliferation assays, to increase proliferation of HUVECs (human umbilical vein endothelial cells) in a bFGF-dose-responsive manner. In these assays, the amount of yellow MTX oxidized to purple formazan is measured spectrophotometrically as a function of the amount of bFGF loaded in the hydrogel. Average increases in formazan salt formation ranged from 1.5 to 4 fold in the bFGF proliferation experiments. In another set of experiments, VEGF released from the PEG-LMW/VEGF hydrogels has been shown to increase the rate of proliferation of porcine aortic endothelial (PAE) cells in DMEM media. Assays were conducted in a transwell assay format as described in N. Yamaguchi, K. L. Kiick, Polysaccharide-poly(ethylene glycol) star copolymers as scaffolds for the production of bioactive hydrogels, Biomacromolecules 6 (4) (2005) 1921-1930. Measured increases in the proliferation rate, assessed via cytometry, have ranged from 25-50%. These results complement and are similar to the results obtained in Example 3, which indicate the bioactivity of growth factor-loaded electrospun matrices. Similar bioactivity of any growth factor sequestered in these matrices is expected, based on these results, and on the general observation of growth factor activity preservation in heparinized matrices.

Example 5
Electrospinning Fibers of Polyurethane or Collagen

Methods for preparing electrospun polyurethane fibers are known in the art, e.g., Rockwood, et al., J. Biomaterials Science, Polymer Edn. 18: 743-758, 2007. Briefly, an 18% wt/vol solution of polyurethane (PU) was prepared in dichloromethane. Microfibers were spun on an electrospinning apparatus consisting of a syringe pump (Orion Sage™, Fisher, Fair Lawn, N.J.), high voltage supply (Glassman Series EH, High Bridge, N.J.), 5 ml glass syringe with a 23 gauge stainless steel needle attached at a working distance of 25 cm. A voltage of 10 kV was applied between the needle and the grounded collector plate. Large mats of electrospun fibers were collected on a grounded mandrel that slowly oscillated in the transverse direction at 5 m/sec and rotated at 0.133 m/sec. Smaller mats were collected on a stationary target.

Electrospun collagen fibers were prepared as previously described, Hartman, et al., Biomacromolecules 10: 2019-2032, 2009. Briefly, collagen fibers were electrospun from a 12% wt/vol solution of collagen type I in hexafluoroisopropanol using the same processing parameters as described in Example 1. LMWH-PEG was incorporated into the fiber as described in Example 1 and in Casper, et al., Biomacromolecules 6: 1998-2007, 2005.

Example 6
Release of Growth Factors from Electrospun Fibers
Platelet derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) were obtained commercially from R&D Systems, Minneapolis, Minn. Vascular epidermal growth factor (VEGF165) was expressed from E. coli with the glycine residues of the growth factor replaced by 3H-glycine. 3H-VEGF165 was produced by E. coli grown on minimal medium that was supplemented with 3H-glycine just prior to induction of protein expression. All samples were 6 mm disks of approximately 1 mg mass. All heparin species were at 100 µM concentration. Growth factor release studies were carried out using scintillation counting (V.E.G.F) or enzyme immunoassay (PDGF and bFGF). Growth factor binding to the electrospun PLGA, PU and collagen matrices was performed in 24-well polystyrene plates (Corning Inc., Corning, N.Y.) with 8 µm pore size transwell membranes (Fisher Scientific, Atlanta, Ga.) to keep the electrospun matrices submerged during the release study. The 24 well plate and transwell membranes were blocked with a 3% BSA (Sigma Aldrich, St. Louis, Mo.) in PBS (Invitrogen, Carlsbad, Calif.) solution for 24 hours. All samples were washed three times with PBS and then incubated with 100 ng growth factor in 1 ml PBS for 2 hours at room temperature with the transwell membrane in place. After 2 hours of incubation the PBS was removed and replaced with 1 ml of PBS containing no growth factor. All samples were incubated at 37°C in a humid atmosphere with 5% CO2 in a NACPO 6000 incubator. Each 1 ml aliquot of PBS was removed from the 24 well plate on a 24 hour basis to determine the amount of growth factor released in that time period. Each well was refilled with 1 ml of fresh PBS after each aliquot was removed for scintillation counting. Serum-free DMEM may be used as an alternative to PBS in these experiments.

To measure 3H-VEGF165, aliquots were placed in 10 ml scintillation vials with 5 ml of Fisher ScintiSafe Econo 2 scintillation fluid (Fisher Scientific, Atlanta, Ga.), vortexed for 30 seconds and counted for 1 minute in a Beckman Coulter LS6500 (Beckman Coulter, Brea, Calif.) scintillation counter to determine the rate of growth factor release during each time interval. Commercially available assay kits from R&D Systems were used to measure released PDGF and
bFGF. Release values are based on the total amount of growth factor in each fibrous mat prior to the release studies. Heparinized mats sequestered about 100% of the growth factor initially applied, while non-heparinized mats sequestered about 50-57% of the applied growth factor. Release profiles for VEGF, PDGF, and bFGF are shown in FIG. 24. Approximate release values over 7 days were 20% for PDGF and VEGF and 40% for bFGF, corresponding, in these examples, to approximately 20 ng of PDGF or VEGF and 40 ng of bFGF. Electrospun fibers modified with high molecular weight heparin (HMWH) showed almost complete release (100%) of growth factor within 2 days. In contrast, matrices modified with PEG-LMWH showed a linear release of growth factor over a period greater than 7 days. Electrospun fibers modified with free LMWH (not conjugated to PEG) exhibited release profiles similar to those seen in non-heparinized mats. These results demonstrate that the conjugation of LMWH to a short polymeric chain permits facile functionalization of fibers, retention of PEG-LMWH to provide functional activity of LMWH in the matrices, and thus allows for retention and significantly slowed release of growth factors from the matrix over time.

### SEQUENCE LISTING

<table>
<thead>
<tr>
<th>SEQ ID NO</th>
<th>LENGTH</th>
<th>TYPE</th>
<th>ORGANISM</th>
<th>FEATURE</th>
<th>OTHER INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>34</td>
<td>PRT</td>
<td>Artificial sequence</td>
<td>Synthetic peptide</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>15</td>
<td>PRT</td>
<td>Homo sapiens</td>
<td>Ala is beta-alanine</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>16</td>
<td>PRT</td>
<td>Homo sapiens</td>
<td>Synthetic peptide</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>12</td>
<td>PRT</td>
<td>Artificial sequence</td>
<td>Synthetic peptide</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>7</td>
<td>PRT</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
What is claimed:

1. A functionalized polymer matrix for the controlled release in vitro or in vivo of a growth factor, the functionalized polymer matrix comprising a matrix polymer, a compatibilizing polymer comprising PEG, a low molecular weight heparin and at least one releasable growth factor, wherein the low molecular weight heparin is covalently attached to the compatibilizing polymer, and wherein the compatibilizing polymer comprises between about 0.35% wt/wt and about 0.95% wt/wt of the polymer matrix, wherein controlled release of the growth factor from the functionalized polymer matrix exhibits a linear controlled-release profile over at least seven days.

2. The functionalized polymer matrix of claim 1, wherein the matrix polymer comprises polyurethane, collagen, PEO, PLGA, or combinations thereof.

3. The functionalized polymer matrix of claim 1, wherein the at least one releasable growth factor is selected from the group consisting of PDGF, VEGF, and bFGF.

4. The functionalized polymer matrix of claim 3, wherein the at least one releasable growth factor is PDGF.

5. The functionalized polymer matrix of claim 3, wherein the at least one releasable growth factor is VEGF.

6. The functionalized polymer matrix of claim 3, wherein the at least one releasable growth factor is bFGF.
7. The functionalized polymer matrix of claim 2, wherein the matrix polymer comprises polyurethane.
8. The functionalized polymer matrix of claim 2, wherein the matrix polymer comprises collagen.
9. The functionalized polymer matrix of claim 2, wherein the matrix polymer comprises PEO.
10. The functionalized polymer matrix of claim 2, wherein the matrix polymer comprises PLGA.

11. The functionalized polymer matrix of claim 1, wherein 50% or less of the growth factor is released from the polymer matrix over seven days.
12. The functionalized polymer matrix of claim 1, wherein the at least one growth factor is non-covalently bound to the low molecular weight heparin.

* * * * *